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(57) ABSTRACT 
In some embodiments, the present invention provides meth-
ods of treating oxidative stress in a subject by administering 
a therapeutic composition to the subject. In some embodi-
ments, the therapeutic composition comprises a carbon 
nanomaterial with anti-oxidant activity. In some embodi-
ments, the anti-oxidant activity of the carbon nanomaterial 
corresponds to ORAC values between about 200 to about 
15,000. In some embodiments, the administered carbon 
nanomaterials include at least one of single-walled nano-
tubes, double-walled nanotubes, triple-walled nanotubes, 
multi-walled nanotubes, ultra-short nanotubes, graphene, 
graphene nanoribbons, graphite, graphite oxide nanorib-
bons, carbon black, oxidized carbon black, hydrophilic 
carbon clusters, and combinations thereof. In some embodi-
ments, the carbon nanomaterial is an ultra-short single-
walled nanotube that is functionalized with a plurality of 
solubilizing groups. In some embodiments, the carbon nano-
material is a polyethylene glycol functionalized hydrophilic 
carbon cluster (PEG-HCC). In some embodiments, the 
administered therapeutic compositions of the present inven-
tion may also include an active agent or targeting agent 
associated with the carbon nanomaterial. Additional 
embodiments of the present invention pertain to the afore-
mentioned carbon nanomaterial compositions for treating 
oxidative stress. 
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1 
USE OF CARBON NANOMATERIALS WITH 
ANTIOXIDANT PROPERTIES TO TREAT 
OXIDATIVE STRESS 
CROSS-REFERENCE TO RELATED 
APPLICATIONS 
2 
transporter moiety that facilitates the transport of carbon 
nanomaterials through a barrier. 
In some embodiments, the methods of the present disclo-
sure may treat oxidative stress by reducing the levels of 
5 reactive oxygen species in the subject. In some embodi-
ments, the methods of the present disclosure may be used to 
reduce the levels of reactive oxygen species in the subject by 
about 5% to about 50%, and particularly at an injured site of 
interest. 
This application claims priority to U.S. Provisional Patent 
Application No. 61/479,293, filed on Apr. 26, 2011. The 
entirety of the aforementioned application is incorporated 10 
herein by reference. 
Additional embodiments of the present disclosure pertain 
to the aforementioned carbon nanomaterial compositions for 
treating oxidative stress. The methods and compositions of 
the present disclosure may be used to treat oxidative stress 
that may be associated with numerous conditions, including, 
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BACKGROUND 
15 without limitation, traumatic brain injury (TBI), ischemia, 
anoxic encephalopathy, hypoxic or ischemic encephalopa-
thy, cerebrovascular dysfunction, hemorrhagic shock, 
hypoxia, hypotension, Alzheimer's disease, Parkinson's dis-
ease, multiple sclerosis, amyotrophic lateral sclerosis (ALS 
20 or Lou Gehrig's disease), liver disease, non-alcoholic fatty 
liver disease, diabetes, stroke, inflammation, spinal cord 
injury (SCI), central nervous system injury (CNSI) or neu-
ropathy, organ transplantation (treatment of the organ or the 
patient) and combinations thereof. Furthermore, the meth-
25 ods and compositions of the present disclosure may be used 
to treat oxidative stress with minimal toxicity and side 
effects. 
Current methods of treating oxidative stress have numer-
ous limitations in terms of efficacy and specificity in target-
ing desired sites. Therefore, a need exists for the develop- 30 
ment of more effective and targeted methods of treating 
BRIEF DESCRIPTION OF THE FIGURES 
FIG. 1 provides illustrations of carbon nanomaterials and 
their anti-oxidant activities. FIG. lA provides structures of 
various carbon nanomaterials. FIG. lB provides a potential 
mechanism by which carbon nanomaterials can scavenge 
oxidative stress. 
BRIEF SUMMARY 
In some embodiments, the present disclosure provides 
methods of treating oxidative stress in a subject by admin-
istering a therapeutic composition to the subject. In some 
embodiments, the therapeutic composition comprises a car-
bon nanomaterial with anti-oxidant activity. In some 
embodiments, the anti-oxidant activity of the carbon nano-
material corresponds to oxygen radical absorbance capacity 
(ORAC) values between about 200 to about 15,000. 
35 free radicals. FIG. lC provides additional structures of 
carbon nanomaterials, their schematic syntheses, and their 
corresponding oxygen radical absorbance capacity (ORAC) 
values. FIG. lD shows a scheme by which polyethylene-
glycol functionalized hydrophilic carbon clusters (PEG-
40 HCCs) and pluronic single-walled nanotubes (pl/SWNTs) 
are prepared. HCCs were generated by treating SWNTs with 
oleum and nitric acid. Following purification, the HCCs 
were functionalized with PEG via coupling to the carboxylic 
acids present on the HCCs, thereby forming PEG-HCCs. In some embodiments, the administered carbon nanoma-
terials in the therapeutic composition include at least one of 
single-walled nanotubes, double-walled nanotubes, triple-
walled nanotubes, multi-walled nanotubes, ultra-short nano-
tubes, graphene, graphene nanoribbons, graphite, graphite 
oxide nanoribbons, carbon black, oxidized carbon black, 
hydrophilic carbon clusters, and combinations thereof. In 50 
some embodiments, the carbon nanomaterial is an ultra-
short single-walled nanotube that is functionalized with a 
plurality of solubilizing groups. In some embodiments, the 
carbon nanomaterial is a hydrophilic carbon cluster (HCC) 
45 The pl/SWNTs were prepared by mixing pluronic with 
SWNTs. FIG. lE shows the structures of various transporter 
moieties and their association with various carbon nanoma-
terials. 
FIG. 2 provides representative fluorescence decay and 
calibration curves. FIG. 2A show fluorescence decay curves 
obtained during the evaluation of vitamin C, caffeic acid, 
catechin, and PEG-HCCs. FIG. 28 shows linear regression 
of net area under the curve (AUC) of trolox corresponding 
to the decay curve A. FIG. 2C provides trolox-measured 
or a polyethylene glycol functionalized hydrophilic carbon 55 
cluster (PEG-HCC). 
In some embodiments, the therapeutic compositions of 
the present disclosure may also include an active agent 
associated with the carbon nanomaterial. In some embodi-
ments, the active agent may be covalently or non-covalently 60 
associated with the carbon nanomaterial. In some embodi-
equivalent (TME) values corresponding to the different 
known antioxidants and carbon nanomaterials, respectively. 
Trolox is the reference compound (TME,rolox=l). 
FIG. 3 provides fluorescence quenching data comparing 
the anti-oxidative properties of PEG-HCCs to various anti-
oxidants. FIG. 3A provides typical fluorescence quenching 
evaluation of PEG-HCCs, PEG chains, and salicylate (SA) 
obtained in each experiment. PEG-HCCs can decrease the 
fluorescence intensity about -20% while PEG can enhance 
it up to -10% on average. These estimations were used for 
ments, the therapeutic compositions of the present disclo-
sure may also include a targeting agent that has recognition 
activity for a marker related to oxidative stress, such as a cell 
surface protein that is up-regulated in response to oxidative 
stress. In some embodiments, the therapeutic compositions 
of the present disclosure may also be associated with a 
65 corrections purposes. FIG. 38 shows benzoate hydroxy-
lation induced by Fe+2 in the presence of ethylenedi-
aminetetraacetic acid (EDTA), 1,8-Diazafluoren-9-one 
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(DFO), PEG-HCCs and PEG. PEG-HCCs and DFO inhibit 
the hydroxylation process at a similar level. In fact, PEG 
also prevents the hydroxylation at the highest concentration 
of the iron. FIG. 3C shows benzoate hydroxylation induced 
by Fe+3 • Again, PEG-HCCs and DFO inhibit the hydroxy- 5 
lation process at a similar level. PEG-HCCs do not induce 
the Fenton reaction. The concentrations used were 0.60 mM 
for EDTA and DFO and 0.02 mg/mL for PEG-HCCs and 
4 
antibody against PEG with an Alexa-633 conjugated sec-
ondary antibody (orange). Each set of images was taken with 
the same settings on a Zeiss LSM 510 confocal microscope, 
and are shown at the same brightness/contrast levels. FIG. 
lOA shows the membrane and nuclei stained cells. FIG. lOB 
shows the PEG-stained cells. FIG. lOC shows the over-
lapped images of the mock treated cells. FIG. lOD shows the 
membrane and nuclei stained cells. FIG. lOE shows PEG-
0.02 mg/mL for PEG. stained cells. FIG. lOF shows overlapped images of the 
FIG. 4 shows the oxidation of ascorbic acid after 5 and 30 10 PEG-treated cells. FIG. lOG shows the membrane and 
min of metal addition in the presence of various compounds, 
as measured by absorbance. Trace metal was likely present 
nuclei stained cells. FIG. lOH shows PEG-stained cells. 
FIG. lOI shows overlapped images of the PEG-HCC-treated 
cells. When PEG-HCC-treated cells were stained with the in the buffer as there were different absorbance values for 
EDTA and DFO compared to no chelator when no extra iron 
was added. Overall, these results show that PEG-HCCs in 
the presence of a reductant such as ascorbate function as 
potent oxidants, regardless of the presence or absence of 
Fe3+. 
secondary antibody only (data not shown), no signal was 
15 observed indicating that there is no non-specific antibody 
staining. 
FIG. 5 shows images of b.End3 endothelial cells, indi-
cating that they express p-selectin when stressed by hista- 20 
mine. Cells were treated with histamine or the diluent 
1 xPBS. Cells were then fixed and stained for the presence of 
p-selectin (green) and DAPI (blue). There was considerably 
enhanced binding of p-selectin antibody following hista-
mine treatment, confirming increased expression of p-selec- 25 
tin. 
FIG. 6 shows images ofb.End3 cells that were oxidatively 
stressed by treatment with histamine or lxPBS. The cells 
were exposed to vehicle, PEG-HCCs or PEG-HCCs con-
taining anti-p-selectin antibodies (ps/PEG-HCCs). The cells 30 
were then stained for the presence of PEG (green) and DAPI 
(blue). There is considerably enhanced binding of anti-PEG 
antibody following histamine treatment indicating enhanced 
binding of the ps/PEG-HCCs to stimulated b.End3 cells. 
FIG. 7 shows that PEG-HCCs and targeted ps/PEG-HCCs 35 
effectively reduce intracellular oxidative stress in b.End3 
endothelial cells. Antimycin A (Ant A) was used to induce 
intracellular superoxide production. Dihydroergotamine 
(DHE) mean fluorescence intensity (indicative of oxidative 
stress) was measured in cells treated with AntA (mean of 5 40 
separate experiments). Results are given as % control 
(DHE+AntA, black bar) to account for minor differences in 
DHE concentrations and laser fluctuations. Untargeted 
(solid grey) PEG-HCCs and targeted ps/PEG-HCCs (striped 
grey) were effective at reducing DHE fluorescence after 45 
AntA treatment, while treatment with a similar amount of 
p-selectin antibody in the absence of PEG-HCCs (striped 
white) was not effective. 
FIG. S shows fluorescence decay and calibration curves. 
FIG. SA shows trolox concentration effect on fluorescence 50 
FIG. 11 shows high resolution images of b.End.3 cells 
treated with PEG-HCC and PEG. Cell nuclei were stained 
with DAPI (blue). Cell membranes were stained with Wheat 
Germ Agglutinin 594 (red). The treated cells were stained 
using a primary antibody against PEG with an Alexa-633 
conjugated secondary antibody (orange). Each set of images 
were taken with the same settings on a Zeiss LSM 510 
confocal microscope, and are shown at the same brightness/ 
contrast levels. FIG. llA shows the membrane and nuclei-
stained cells. FIG. llB shows PEG-stained cells. FIG. llC 
shows overlapped images of the PEG-HCC-treated cells. 
FIG. llD shows the membrane and nuclei stained cells. FIG. 
llE shows PEG-stained cells. FIG. llF shows overlapped 
images of the PEG-treated cells. 
FIG. 12 shows data indicating that PEG-HCCs protect 
brain endothelial cells from oxidative stress when adminis-
tered after an insult. FIG. 12A shows intracellular radical 
oxygen species (ROS) levels for b.End3 cells as determined 
by dihydroethidium (DHE) staining and flow cytometry. The 
mean fluorescent intensity (MFI) of 10,000 cells/group was 
normalized to the group not treated with antimycin A (AntA 
in graphs) or DHE. Phosphate buffered saline (PBS, black 
bar) or antioxidant treatments (blue, green, and red solid 
bars) were given after antimycinA. Some antioxidants were 
administered prior to antimycin A (striped bars). FIG. 12B 
shows cell survival relative to control for b.End3 cells given 
different treatments. The cells were either cultured in the 
presence of PEG-HCCs, PEG-SODs or PBN alone (solid 
bars), or the cells were first treated with a dose of antimycin 
A titrated to kill 30% of the cells followed by treatment with 
PEG-HCCs, PEG-SOD or PBN (striped bars). Results are a 
mean of seven separate experiments. Error bars are s.e.m. 
ANOVA with Bonferroni post test was used to calculate 
statistics. *p-value<0.05. 
FIG. 13 shows DAF-2DA intensity in bEnd.3 cells that 
spontaneously generate nitric oxide (NO) after treatment 
with increasing concentrations of PEG-HCCs. DAF-2DA is 
a NO sensitive dye. FIG. 13A shows that concentrations of 
decay curve induced by 2,2'-azobis(2-amidino-propane) 
dihydrochloride (AAPH). FIG. SB shows PEG-HCCs con-
centration effect on fluorescence decay curve after AAPH 
addition. FIG. SC shows linear regression of net area under 
the curve (AUC) of trolox and PEG-HCC. An approxima-
tion of the Trolox mass equivalent can be estimated dividing 
the slope of the sample by the trolox slope 
(TMEPEG-Hcc=3.12). 
55 PEG-HCCs up to 30 mg/L did not quench NO dye fluores-
cence (p>0.05 for all comparisons). FIG. 13B shows a 
fluorescent microscope image of bEnd.3 cells treated with 
DAF-2DA. Error bars are s.e.m. Scale bar is 50 µm. 
FIG. 9 shows typical fluorescence curves obtained when 
PBS, Trolox, PEG-HCCs, and the fluorescent probe were 
not mixed with AAPH (control 1). Note that fluorescent 
intensity remained stable during the experiment and the 
intensity is not affected by the carbon nanomaterials. 
FIG. 10 shows images of mock, PEG and PEG-HCC-
treated b.End.3 cells. Cell nuclei were stained with DAPI 
(blue), cell membranes with Wheat Germ Agglutinin 594 
(red), and PEG and PEG-HCCs were stained using a primary 
FIG. 14 shows controls for intracellular superoxide (SO) 
60 assay to determine whether there is direct interference 
between the PEG-HCCs and the fluorescent assay. Cells 
were treated with or without antimycin A (a mitochondrial 
toxin that induces SO production). PEG-HCCs were added 
15 min later (grey bars) followed by DHE (SO-specific dye), 
65 as indicated by +. There was no reduction in either non-
specific fluorescence (first three bars) or background fluo-
rescence after addition of DHE (bars 4 and 5). In the last 
US 9,572,834 B2 
5 
combination (bar 6), DHE and antimycin A-treated cells 
demonstrated, as expected, a significantly higher DHE stain-
ing compared to the untreated control (first bar). 
FIG. 15 shows histological and behavioral evidence that 
the combination of traumatic brain injury (TBI) and 5 
hypotension worsens oxidative stress. FIGS. 15A-B provide 
data indicating a large change in lesion volume (noted with 
yellow arrows in A) if TBI is associated with hypotension 
for 40, 50 and 60 min (as recorded 14 days post TBI/ 
hypotension). FIG. 15C provide data indicating a decline of 10 
behavioral abilities tracks with increased duration of 
hypotension. (This data was obtained from Claudia Robert-
son, Md., Baylor College of Medicine). 
FIG. 16 shows data indicating that PEG-HCC treatment 
improves cerebral blood flow (CBF) in the injured cortex in 15 
rats with TBI plus hypotension. The data show CBF in the 
injured cortex (FIG. 16A), the peri-lesional cortex (FIG. 
l6B), and the contralateral cortex (FIG. 16C). Drugs (PEG-
HCC or PBS vehicle) were given where indicated. Time 0 
min indicates when the TBI was performed. The different 20 
phases are indicated as follows: Phase l=TBI+hypotension; 
Phase 2=saline during "prehospital-ambulance phase"; 
Phase 3=blood reinfusion during "definitive-hospital 
phase". Error bars are s.e.m. 
FIG. 17 shows mean arterial pressure (MAP) for rats 25 
undergoing sham surgery or TBI and hemorrhagic shock 
(TBI+HS). Drugs (PEG-HCC or PBS vehicle) were given 
where indicated. Time O min indicates when the TBI was 
performed. The different phases are indicated as follows: 
6 
food intake (in grams) was measured weekly for the six 
week treatment period. Values are mean±SEM. 
FIG. 21 shows that PEG-HCC treatment rapidly restored 
non-fasting glucose levels in ob/ob mice to WT levels. 
Glucose levels were measured prior to treatment (0 weeks of 
treatment) and then weekly for the six week treatment 
regimen. Glucose was measured 5-6 days after vehicle or 
PEG-HCCs treatment each week. Values are mean±SEM. 
FIG. 22 shows that PEG-HCC and Vitamin E (VitE) 
treatment lowered aspartate aminotransferase (AST) levels 
(as compared to vehicle treatment) in mice. Serum was 
collected at baseline and after 2, 4, and 6 weeks of treatment. 
The serum was measured for AST (FIG. 22A), alanine 
aminotransferase (ALT) (FIG. 22B), and alkaline phos-
phatase (ALP) (FIG. 22C) levels. AST levels in ob/ob mice 
were significantly lowered by PEG-HCCs and Vitamin E. 
Vitamin E also had a transiently lower ALT level after 4 
weeks of treatment. ALT levels were not changed by treat-
ment. Values are mean±SEM. Green asterisks indicate sig-
nificant differences between vehicle versus Vitamin E 
treated ob/ob mice, while blue asterisks indicate differences 
between vehicle and PEG-HCC treated ob/ob mice. 
**p<0.01; ***p<0.001. 
FIG. 23 shows that PEG-HCC and Vitamin E treatment 
for six weeks in ob/ob mice lowered lipid peroxidation 
levels compared to vehicle treated ob/ob mice. Serum from 
mice treated with vehicle, PEG-HCCs, or Vitamin E for six 
weeks was analyzed using a TBARS assay to measure 
malondialdehyde (MDA) levels. MDA is used as a marker 
Phase 1 =TBI+hypotension; Phase 2=PBS during "pre-hos-
pital-ambulance phase"; and Phase 3=blood reinfusion dur-
ing "definitive-hospital phase." No statistical differences 
(p-value>0.05) were seen with data calculated with repeated 
measures. 
30 for lipid peroxidation. PEG-HCCs and Vitamin E lowered 
MDA levels in ob/ob mice compared to vehicle treatment. 
Values are mean±SEM. 
FIG. 24 shows that hepatic lipid levels in mice were 
unchanged by the vehicle, PEG-HCCs, or Vitamin E regi-
FIG. 18 shows the levels of superoxide (SO) and nitric 
oxide (NO) recorded in the brain and vasculature. DHE 
levels (proportional to SO and oxidative radicals) in the 
brain (cortex) (FIG. 18A) and blood vessels (FIG. l8B) of 
sham surgery rats or rats with TBI+hypotension with vehicle 
35 men after six weeks. The levels of cholesterol (FIG. 24A), 
free fatty acids (FIG. 248), triglycerides (FIG. 24C), and 
cholesteryl esters (FIG. 24D) were higher in ob/ob mice 
compared to WT but unchanged by six weeks of treatment. 
Values are mean±SEM. 
or PEG-HCC treatment are shown. The vehicle-treated and 40 
sham groups were controls. The ipsilateral cortex (region 
with TBI) was normalized to the contralateral cortex. PEG-
HCC treatment (blue) was able to reduce DHE staining 
compared to vehicle treatment (red), with a larger magnitude 
of effect seen in the blood vessels, which is likely the site of 45 
cerebrovascular dysfunction evident in the TBI model. FIG. 
18C shows microscopy ofDHE staining (red) in the injured 
cortex (scale bar=200 µm). Similarly, DAF-2DA levels 
(indicative of NO levels) are shown in brain (cortex) (FIG. 
18D) and blood vessels (FIG. 18E) of sham surgery rats or 50 
rats with TBI+hypotension with vehicle or PEG-HCCs 
treatment. Microscopy ofDAF-2DA staining (green) in the 
injured cortex is shown in FIG. 18F. Scale bar=200 µm. 
FIG. 19 shows Laser Doppler flowmetry (LDF) results 
relating to treatment of rat models ofTBI with two doses of 55 
PEG-HCCs. FIG. 19A shows that a second dose of PEG-
FIG. 25 shows pl/SWNTs and PEG-HCCs quench super-
oxide. FIG. 25A shows a table of IC50 values for the 
oxidation of cytochrome c by superoxide. FIG. 258 shows 
nonlinear regression plots from separate experiments mea-
suring the rate of cytochrome c oxidation relative to the log 
of the concentration of the carbon core of pl/SWNTs and 
PEG-HCCs. 
FIG. 26 shows toxicity studies ofSWNTs and PEG-HCCs 
with b.End3 cells. FIG. 26A shows an image identifying 
cultured b.End3 cells as endothelium based on expression of 
Von Willebrand Factor (red). Blue stain (DAPI) indicates 
cell nuclei. FIG. 268 shows data relating to the survival of 
b.end3 cells treated with various concentrations of PEG-
HCCs or pl/SWNTS, as measured by trypan blue staining. 
FIG. 26C shows data relating to the survival ofb.end3 cells 
treated with various concentrations of PEG-HCCs, 
pl/SWNTs or 1 % pluronic, as measured by a clonogenic 
survival assay. 
FIG. 27 shows a table of controls for intracellular super-
oxide assay to determine whether there is direct interference 
HCCs (administered 2 hours from the first dose) sustains 
CBF in rat models. FIG. l9B shows that the relative CBF in 
the uninjured contralateral cortex was similar between 2 
dose PEG-HCCs and vehicle-treated rats (104.1±6.9 and 
93.5±5.9, respectively). FIG. 19C shows that the mean 
arterial blood pressure (MAP) was not significantly different 
between the groups. 
60 between the carbon nanomaterials and the fluorescent assay. 
FIG. 20 shows data indicating that the body weight (FIG. 
20A) and food intake (FIG. 20B) in wild-type (WT) and 
ob/ob mice are not altered by treatment with vehicle, PEG-
HCCs, or Vitamin E chow for six weeks. Body weight and 
Cells were treated with or without antimycin A (vertical 
striped bars). PEG-HCCs or pl/SWNTs were added fifteen 
minutes later (light and dark grey bars, respectively), fol-
lowed by DHE (horizontal striped bars) where indicated. 
65 There did not appear to be any reduction in either non-
specific fluorescence (first three bars) or background fluo-
rescence after addition of DHE (bars 5-8). The last combi-
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nation, DHE and antimycin A treated (vertical and 
horizontal striped bar) demonstrated, as expected, a signifi-
cantly higher DHE staining compared to the untreated 
control (white solid bar). 
FIG. 28 shows intracellular ROS levels for b.End3 cells as 
determined by DHE staining and flow cytometry. Superox-
ide production was induced using antimycin A, and super-
oxide levels were measured with the superoxide-specific 
dye, DHE. Neither the PEG-HCCs nor the pl/SWNTs alone 
altered the DHE fluorescence. The level of DHE fluores-
cence in cells not treated with antimycinA (solid white bar) 
was significantly lower than the fluorescence in antimycin 
A-treated cells (grey bar+PBS) indicating higher superoxide 
levels in antimycin A-treated cells. Following antimycin A 
exposure, treatment with PEG-HCCs (grey bars+PEG-
HCCs) or pl/SWNTs (grey bars+pl/SWNTs) reduced the 
level of ROS in a dose dependent manner (doses for anti-
oxidant treatments are located below the bars). Following 
antimycin A exposure, treatment with PEGylated SOD (grey 
bar+SOD) or PBN (grey bar+PBN) at similar concentrations 
8 
trative and explanatory, and are not restrictive of the subject 
matter, as claimed. In this application, the use of the singular 
includes the plural, the word "a" or "an" means "at least 
one", and the use of"or" means "and/or", unless specifically 
5 stated otherwise. Furthermore, the use of the term "includ-
ing", as well as other forms, such as "includes" and 
"included", is not limiting. Also, terms such as "element" or 
"component" encompass both elements or components com-
prising one unit and elements or components that comprise 
10 more than one unit unless specifically stated otherwise. 
The section headings used herein are for organizational 
purposes and are not to be construed as limiting the subject 
matter described. All documents, or portions of documents, 
cited in this application, including, but not limited to, 
15 patents, patent applications, articles, books, and treatises, are 
hereby expressly incorporated herein by reference in their 
entirety for any purpose. In the event that one or more of the 
incorporated literature and similar materials defines a term 
in a manner that contradicts the definition of that term in this 
by weight to the dose of the maximally effective nanoma- 20 
terials had no statistically significant effect. However, pre-
treatment with a higher dose (40 U/L PEGylated SOD and 
1100 mg/L PBN, striped grey bars) along with the standard 
treatment at that same elevated dose reduced the level of 
ROS. All statistics are compared to the bar with an arrow 25 ( +PBS grey bar). *p-value<0.05; **p-value<0.01; ***p-
value<0.001. 
application, this application controls. 
Damage to the vasculature caused by oxidative stress is a 
significant contributor to a variety of neurological compli-
cations, including ischemia and traumatic brain injury. 
Elevated levels ofreactive oxygen species (ROS), including 
reactive free radicals derived from them, are a cause of the 
oxidative stress, as they are capable of damaging lipids, 
proteins and nucleic acids. Furthermore, ROS-initiated reac-
tions, such as lipid peroxidation, can establish a prolonged 
propagation of free radical-mediated injuries to various 
FIG. 29 is a table of intracellular ROS levels and statistics 
for b.End3 cells, as determined by DHE staining and flow 
cytometry. Superoxide production was induced using anti-
mycin A, and superoxide levels were measured with the 
superoxide-specific dye, DHE. All results were calculated as 
percent control from non-antimcyin A and non-D HE treated 
cells (100% ). All statistics are compared to the PBS+ 
Antimcyin A treated group. 
FIG. 30 shows cell survival relative to control for b.End3 
cells given different treatments. The cells were either cul-
tured in the presence of PEG-HCCs, pl/SWNTs, PEGylated 
SOD or PBN alone (white bars). Alternatively, the cells were 
first treated with a dose of antimycin A titrated to kill 30% 
of the cells followed by treatment with PEG-HCCs, 
pl/SWNTs, PEGylated SOD or PBN (grey bars). The PEG-
HCCs were most effective at protecting the cells. Additional 
statistical findings are provided in FIG. 31. *p-value<0.05. 
30 cells, tissues and organs. 
Antioxidant therapies have been investigated for treating 
oxidative stress, including traumatic brain injury. For 
instance, extensive research has explored using small mol-
ecule antioxidants, such as phenyl N-tert-butyl nitrone 
35 (PBN), or stabilized enzymes, such as polyethylene func-
tionalized superoxide dismutase (PEG-SOD), to combat 
oxidative stress. However, these potential therapies have 
shown limited efficacy in clinical trials. Furthermore, there 
are limited Food and Drug Administration-approved anti-
40 oxidant therapies for these conditions. Therefore, a need 
exists for new methods and therapeutic compositions for 
treating oxidative stress. The present disclosure addresses 
this need. 
FIG. 31 show a table summarizing cell survival numbers 
relative to control and statistics for b.End3 cells given 45 
different treatments. Bold lettering indicates statistics dis-
played in FIG. 30 (n.s.=not significant). 
In some embodiments, the present disclosure provides 
methods of treating oxidative stress in a subject by admin-
istering to the subject a therapeutic composition that 
includes a carbon nanomaterial with anti-oxidant activity. 
Additional embodiments of the present disclosure pertain to 
the therapeutic compositions that are administered to the 
FIG. 32 provides control data indicating survival of 
b.end3 cells treated with various concentrations of pluronic, 
as measured by a clonogenic survival assay. 
subject. The methods and compositions of the present dis-
closure may be used to treat oxidative stress that is associ-
ated with various conditions, including, without limitation, 
traumatic brain injury (TBI), ischemia, anoxic encephalopa-
thy, hypoxic or ischemic encephalopathy, cerebrovascular 
FIG. 33 shows data indicating that treatment with PEG- 50 
HCCs reduced ROS formation in the brains of 14-15Tg2576 
mice. Mice were injected i.p. with vehicle (Control) or 
PEG-HCCs. The dose of PEG-HCCs was 200 RI of 150 
mg/I solution. Mice were injected at 24 and 48 hours prior 
55 dysfunction, hemorrhagic shock, hypoxia, hypotension, 
Alzheimer's disease, Parkinson's disease, multiple sclerosis, 
amyotrophic lateral sclerosis (ALS or Lou Gehrig's dis-
ease), liver disease, non-alcoholic fatty liver disease (NA-
FLD), diabetes, stroke, inflanimation, spinal cord injury 
to euthanasia (DHE was administered at the 24 hour time 
point). Mice were euthanized and the DHE/DAPI ratio in the 
hippocampus was assessed. A significant increase in DHE 
staining in the TG2576 mice was observed, indicating 
increased ROS formation. However, in Tg2576 mice treated 
with PEG-HCCs, a normalization of the DHE staining was 
observed, indicating that ROS formation was reduced back 
to wild-type levels. 
DETAILED DESCRIPTION 
It is to be understood that both the foregoing general 
description and the following detailed description are illus-
60 (SCI), central nervous system injury (CNSI) or neuropathy, 
organ transplantation (treatment of the organ or the patient) 
and combinations thereof. 
Additional support for the embodiments of the present 
disclosure can also be found in the following of Applicants' 
65 co-pending patent applications: PCT/US2008/078776, 
entitled "Water Soluble Carbon Nanotube Compositions for 
Drug Delivery and Medical Applications"; and PCT/ 
US 9,572,834 B2 
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US2010/054321, entitled "Therapeutic Compositions and 
Methods for Targeted Delivery of Active Agents." Also see 
U.S. patent application Ser. Nos. 12/245,438 and 12/280, 
523. 
Therapeutic Compositions 
Various embodiments of the present disclosure pertain to 
therapeutic compositions for treating oxidative stress. As set 
forth in more detail below, such therapeutic compositions 
can have numerous variations. In some embodiments, the 
therapeutic compositions of the present disclosure include a 
carbon nanomaterial with anti-oxidant activity. In some 
embodiments, the carbon nanomaterials of the present dis-
closure may also be associated with one or more active 
agents, such as anti-oxidants. In some embodiments, the 
carbon nanomaterials of the present disclosure may also be 
associated with one or more targeting agents, such as 
targeting agents that have recognition activity for a marker 
related to oxidative stress. 
Carbon Nanomaterials 
Carbon nanomaterials suitable for use in the therapeutic 
compositions of the present disclosure generally refer to 
particles that have anti-oxidant activity. Structures of suit-
able and non-limiting carbon nanomaterials are shown in 
FIG. lA. 
10 
transport of a carbon nanomaterial to a site of interest. For 
instance, in some embodiments, the transporter moiety may 
be a molecule that facilitates the transfer of a carbon 
nanomaterial through the blood brain barrier (BBB) or the 
5 blood spinal cord barrier (BSB). In some embodiments, the 
transporter moiety may be a BBB or BSB transporter, such 
as an adamantane molecule or an adamantane derivative, 
including, without limitation, amantadine, memantine, rim-
antadine, dopamantin, tromantadine, vildagliptin, karman-
10 tadin, and combinations thereof. Exemplary structures of 
adamantane molecules are shown in FIG. lE (upper panel). 
In some embodiments, the BBB or BSB transporter 
moiety may include a cannibinoid molecule or a cannibinoid 
derivative, including, without limitation, cannabigerol, can-
15 nabigerol monomethyl ether, carmabinerolic acid A, cannab-
igerovarin, cannabigerolic acid A, cannabigerolic acid A 
monomethyl ether, cannabigerovarinic acid A, cannabi-
chromene, cannabichromenic acid A, cannabivarichromene, 
carmabichromevarin, cannabichromevarinic acid A, canna-
20 bidiol, cannabidiol momomethyl ether, carmabidiol-C4 , can-
nabidivarin, cannabidiorcol, carmabidiolic acid, carmabidi-
var1mc acid, carmabinodiol, carmabinodivarin, 
carmabivarin, carmabicitran, HU-210 and combinations 
thereof. In some embodiments, the BBB or BSB transporter 
25 moiety may be a synthetic cannabinoid derivative that is the 
"urmatural" enantiomer of a cannabinoid, such as dexanabi-
nol (HU-211), which is a synthetic carmabinoid derivative 
that is the "urmatural" enantiomer of the potent cannabinoid 
In some embodiments, suitable carbon nanomaterials 
include, without limitation, single-walled nanotubes 
(SWNTs ), double-walled nanotubes (DWNTs ), triple-walled 
nanotubes (TWNTs), multi-walled nanotubes (MWNTs), 
ultra-short nanotubes, ultra-short single-walled nanotubes 
(US-SWNTs), hydrophilic carbon clusters (HCCs), gra- 30 
phene nanoribbons, graphite, graphite oxide nanoribbons, 
carbon black, derivatives thereof, and combinations thereof. 
agonist HU-210. 
Transporter moieties may be associated with carbon nano-
materials in various manners. In some embodiments, the 
transporter moieties may be covalently linked to the ends or 
sidewalls of carbon nanomaterials. In various embodiments, 
the covalent linkage may occur directly or through a linker 
35 molecule. In some embodiments, the transporter may be 
associated with the end of the solubilizing chain, as shown 
in FIG. 1E (e.g., lower panel, showing ADA-PEG-HCC). In 
some embodiments, one or more transporter moieties may 
In some embodiments, the carbon nanomaterials of the 
present disclosure may be modified in various ways. For 
instance, in some embodiments, the carbon nanomaterials of 
the present disclosure may be oxidized. In some embodi-
ments, the carbon nanomaterials of the present disclosure 
may be functionalized with one or more molecules, poly-
mers, chemical moieties, solubilizing groups, functional 
groups, and combinations thereof. For instance, in some 40 
embodiments, the carbon nanomaterials of the present dis-
closure may be functionalized with ketones, alcohols, epox-
ides, carboxylic acids, and combinations thereof. 
be non-covalently linked to carbon nanomaterials. 
In more specific embodiments, the carbon nanomaterials 
of the present disclosure include US-SWNTs. US-SWNTs 
are also referred to as hydrophilic carbon clusters (HCCs). 
Therefore, for the purposes of the present disclosure, US-
SWNTs are synonymous with HCCs. In some embodiments, In more specific embodiments, the carbon nanomaterials 
of the present disclosure may be functionalized with a 
plurality of solubilizing groups. In further embodiments, the 
solubilizing groups may include at least one of polyethylene 
glycols (PEGs), polypropylene glycol (PPG), poly(p-phe-
nylene oxide) (PPOs), polyethylene imines (PEI), poly(vinyl 
alcohol) (PVA), poly(acrylic acid) (PAA) and combinations 
thereof. In some embodiments, the carbon nanomaterials of 
the present disclosure can include PEG-functionalized 
HCCs (i.e., PEG-HCCs, as described in more detail below). 
In some embodiments, the solubilizing groups or func-
tional groups may be covalently associated with the carbon 
nanomaterials. In some embodiments, the solubilizing 
groups or functional groups may be non-covalently associ-
ated with the carbon nanomaterials. In more specific 
embodiments, carbon nanomaterials may include SWNTs 
that are non-covalently wrapped with a plurality of solubi-
lizing groups, such as PEGs or pluronic (PEG-PPG-PEG). In 
some embodiments, the carbon nanomaterials may include 
pluronic wrapped SWNTs (pl/SWNTs). 
In some embodiments, the carbon nanomaterials of the 
present disclosure may also be associated with one or more 
transporter moieties. Transporter moieties generally refer to 
molecules or functional groups that facilitate or promote the 
45 HCCs can include oxidized carbon nanoparticles that are 
about 30 nm to about 60 nm long, and approximately 1-2 nm 
wide. 
In some embodiments, US-SWNTs (i.e., HCCs) may be 
produced by reacting SWNTs in fuming sulfuric acid with 
50 nitric acid to produce a shortened carbon nanotube charac-
terized by opening of the nanotube ends. Such methods are 
disclosed in Applicants' co-pending U.S. patent application 
Ser. No. 12/280,523, entitled "Short Functionalized, Soluble 
Carbon Nanotubes, Methods of Making Same, and Polymer 
55 Composites Made Therefrom." This may be followed by the 
functionalization of the plurality of carboxylic acid groups. 
In some embodiments, the HCC may be an oxidized gra-
phene. 
In some embodiments, the HCCs may be functionalized 
60 with one or more solubilizing groups, such as PEGs, PPOs, 
PEis, PVAs, PAAs, and combinations thereof (as previously 
described). In more specific embodiments, the carbon nano-
materials of the present disclosure may include polyethylene 
glycol-functionalized HCCs (PEG-HCCs). Various PEG-
65 HCCs and methods of making them are disclosed in the 
following articles and patent applications: Berlin et al., ACS 
Nano 2010, 4, 4621-4636; Lucente-Schultz et al., J. Am. 
US 9,572,834 B2 
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Chem. Soc. 2009, 131, 3934-3941; Chen et al.,J. Am. Chem. 
Soc. 2006, 128, 10568-10571; Stephenson, et al., Chem. 
Mater. 2007, 19, 3491-3498; Price et al., Chem. Mater. 2009, 
21, 3917-3923; PCT/US2008/078776; and PCT/US2010/ 
054321. 
In some embodiments, HCCs and PEG-HCCs may also 
12 
entrapment or sequestration of oxidants or pre-oxidants, 
such as metals. In some embodiments, carbon nanomaterial 
anti-oxidant activity may occur by sequestering or scaveng-
ing free radicals. 
In addition, the carbon nanomaterials of the present 
disclosure may scavenge free radicals by various mecha-
nisms. In some embodiments, it is envisioned that the carbon 
core of the carbon nanomaterials can scavenge free radicals. 
For instance, as illustrated in FIG. lB, conjugated domains 
be associated with one or more transporter moieties (as 
previously described). For instance, in some embodiments, 
the ends or sidewalls of HCCs or PEG-HCCs can be 
covalently linked to an adamantane or cannabinoid molecule 
to facilitate its transfer through the BBB or BSB. See, e.g., 
FIG. 1E (lower panel). 
10 in the carbon core of carbon nanomaterials may receive two 
RO• species. As a result, two carbon-carbon pi-bonds could 
be lost, but two new C---0 sigma bonds and one new C----C 
pi bond could be formed without any radical species remain-In various embodiments, PEG-HCCs (and other function-
alized forms of HCCs) may have various advantageous 
properties for use as carbon nanomaterials. For instance, 15 
PEG-HCCs (and other functionalized forms of HCCs) may 
demonstrate low biological toxicity with clearance mainly 
through the kidneys. PEG-HCCs (and other functionalized 
forms of HCCs) may also contain hydrophobic domains that 
can be non-covalently loaded with active agents, such as 20 
hydrophobic active agents. In addition, PEG-HCCs (and 
other functionalized forms of HCCs) can have an ability to 
strongly bind to various targeting agents (such as monoclo-
nal or IgG-type antibodies) without significantly interfering 
with the activity of the targeting agents. 
ing. 
In some embodiments, polymer chains appended to the 
carbon nanomaterials may scavenge free radicals. In some 
embodiments, the radical scavenging may lead to the deg-
radation of the polymer chains, as previously reported. Proc. 
Nat. Acad. Sci. USA, 1998 (95):10373-10377. 
In some embodiments, the anti-oxidant activity of the 
carbon nanomaterial may correspond to oxygen radical 
absorbance capacity (ORAC) values between about 200 to 
about 15,000. In some embodiments, the anti-oxidant activ-
ity of the carbon nanomaterial may correspond to ORAC 
25 values between about 200 and about 5,000. In some embodi-
ments, the anti-oxidant activity of the carbon nanomaterial 
may correspond to ORAC values between about 300 and 
about 400. 
Other suitable PEGylated or functionalized carbon nano-
materials can also be used as carbon nanomaterials. Non-
limiting examples include PEGylated graphite oxide nan-
oribbons (PEG-GONR), PEGylated oxidized carbon black 
(PEG-OCB), and PEGylated carbon black (PEG-CB). Addi- 30 
tional suitable carbon nanomaterials, including PEG-HCCs, 
are disclosed in U.S. patent application Ser. No. 12/245,438; 
PCT/US2008/078776; and PCT/US2010/054321. The use 
Exemplary ORAC values of suitable but non-limiting 
carbon nanomaterials are listed in FIG. lC. As illustrated, 
the ORAC values of the carbon nanomaterials of the present 
disclosure can be about 100 times to about 1000 times more 
potent than current anti-oxidant therapies. For instance, 
amifostine alone has an ORAC value of about 2.5. of other suitable carbon nanomaterials not disclosed here 
can also be envisioned. 
The carbon nanomaterials of the present disclosure may 
have various properties. For instance, in some embodiments, 
the carbon nanomaterial may be hydrophilic (i.e., water 
soluble). In some embodiments, the carbon nanomaterials of 
the present disclosure may have both hydrophilic portions 
and hydrophobic portions. For instance, in some embodi-
ments, the carbon nanomaterials of the present disclosure 
may have a hydrophilic domain ( e.g, a hydrophilic surface) 
and a hydrophobic domain (e.g., a hydrophobic cavity). The 
carbon nanomaterials of the present disclosure can also be 
engineered to possess both hydrophobic and hydrophilic 
domains, combining high aqueous solubility with the ability 
35 Active Agents 
In various embodiments, the therapeutic compositions of 
the present disclosure may also include one or more active 
agents. Active agents of the present disclosure generally 
refer to biologically active compounds, such as compounds 
40 that have anti-oxidant activity. For instance, in various 
embodiments, active agents of the present disclosure may 
refer to anti-cancer drugs, chemotherapeutics, antioxidants, 
and anti-inflammatory drugs. 
Furthermore, the active agents of the present disclosure 
45 may be derived from various compounds. For instance, in 
various embodiments, the active agents of the present dis-
closure can include, without limitation, small molecules, 
proteins, aptamers, DNA, anti-sense oligo nucleotides, to adsorb hydrophobic compounds. In some embodiments, 
this duality of hydrophilic and hydrophobic domains can 
result in the formation of structures resembling micelles or 50 
liposomes. Such structures can in turn further entrap active 
agents (such as small drugs) for delivery to a desired site. 
Hence, an active agent (such as a small molecule drug) can 
have its own efficacy (e.g., a chemotherapeutic activity) in 
conjunction with the anti-oxidant activity of the carbon 
nanomaterial. 
miRNA, siRNA, and combinations thereof. 
In more specific embodiments, the active agents of the 
present disclosure may include one or more anti-oxidants. In 
some embodiments, the anti-oxidants may include, without 
limitation, ascorbic acid (Vitamin C), glutathione, lipoic 
acid, uric acid, carotenes, ~-carotenes, retinal (Vitamin A), 
55 tocopherols, tocotrienols, a-Tocopherol (Vitamin E), 
ubiquinol ( coenzyme Q), melatonin, carotenoids, lycopenes, 
carotenes, luteins, phenyl N-tert-butyl nitrone (PBN), tirila-
zad mesylate, tirilizad, propyl gallate, tertiary butylhydro-
quinone (TBHQ), butylated hydroxyanisole (BHA), buty-
The carbon nanomaterials of the present disclosure may 
also demonstrate very low or limited toxicity in vivo. 
Furthermore, and as set forth in more detail below, the 
carbon nanomaterials of the present disclosure can have 
anti-oxidant activity. 
Carbon Nanomaterial Anti-Oxidant Activity 
Carbon nanomaterial anti-oxidant activity generally refers 
to a carbon nanomaterial's ability to prevent oxidation, limit 
oxidation or eliminate oxidation. Such activities may occur 
by various mechanisms. For instance, in some embodiments, 
carbon nanomaterial anti-oxidant activity may occur by the 
60 lated hydroxytoluene (BHT), combinations thereof, and 
derivatives thereof. In further embodiments, anti-oxidants 
may also include enzymes, such as SOD, PEG-SOD, cata-
lase and peroxiredoxins. 
In some embodiments, the active agents of the present 
65 disclosure may also include one or more active agents that 
treat various conditions associated with oxidative stress. For 
instance, in some embodiments, the therapeutic composi-
US 9,572,834 B2 
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some embodiments, therapeutic compositions of the present 
disclosure may include multiple active agents. In some 
embodiments, therapeutic compositions of the present dis-
closure may include carbon nanomaterials without any 
active agents. 
Tracers 
tions of the present disclosure may include active agents that 
treat traumatic brain injury, ischemia, anoxic encephalopa-
thy, hypoxic or ischemic encephalopathy in neonates, cere-
brovascular dysfunction, hemorrhagic shock, hypoxia, 
hypotension, Alzheimer's disease, Parkinson's disease, mu!- 5 
tiple sclerosis, amyotrophic lateral sclerosis, liver disease, 
non-alcoholic fatty liver disease, diabetes, stroke, inflam-
mation, spinal cord injury, central nervous system injury or 
neuropathy, organ transplantation (treatment of the organ or 
the patient), or combinations of such conditions. 
In more specific embodiments, the therapeutic composi-
tions of the present disclosure may include riluzole as an 
active agent for treatment of conditions associated with 
amyotrophic lateral sclerosis. In further embodiments, the 
therapeutic compositions of the present disclosure may 15 
include anti-oxidants, anti-inflanmiatory drugs, anti-cancer 
drugs, anti-diabetic drugs, and combinations thereof. 
The therapeutic compos1t10ns of the present disclosure 
can also be associated with one or more tracers, such as an 
MRI tracer. In more specific embodiments, the tracer(s) 
10 
associated with therapeutic compositions may include a 
gadolinium tracer, such as Gd3+. In further embodiments, 
the tracer may include, without limitation, at least one of 
fluorescent molecules, Qdots, radioisotopes, and combina-
In addition, the active agents of the present disclosure 
may have various secondary properties. For instance, in 
some embodiments, the active agents may be hydrophobic. 20 
In fact, an advantage of the carbon nanomaterials of the 
present disclosure is the effective delivery of hydrophobic 
active agents that may have been otherwise insoluble. Such 
hydrophobic agents can be associated with various carbon 
nanomaterials for direct delivery to a desired site without 25 
requiring the use of moieties that increase solubility but limit 
active agent efficacy. 
tions thereof. In various embodiments, such tracers can be 
used to track in real-time the location, distribution and 
delivery of administered therapeutic compositions. Thus, 
such embodiments would allow a physician to follow the 
degree of therapeutic composition binding to desired sites, 
monitor the biological half-life of the therapeutic composi-
tions, and monitor accumulation in non-target organs such 
the kidney and liver. 
Targeting Agents 
The therapeutic compositions of the present disclosure 
may also be associated with one or more targeting agents. 
Targeting agents of the present disclosure generally refer to 
compounds that have recognition activity for a marker, such 
as one or more markers related to oxidative stress. There-
fore, targeting agents of the present disclosure may be 
utilized in various embodiments to direct therapeutic com-
positions to desired sites that are associated with oxidative 
stress. 
In various embodiments, targeting agents may include, 
In addition, the active agents of the present disclosure 
may be associated with carbon nanomaterials in various 
manners. For instance, in some embodiments, the active 30 
agents may be non-covalently associated with carbon nano-
materials, such as through sequestration, adsorption, ionic 
bonding, dipole-dipole interactions, hydrogen bonding, Van 
der Waals interactions, and other types of non-covalent 
associations. 35 without limitation, antibodies, RNA, DNA, aptamers, small 
molecules, dendrimers, proteins, and combinations thereof. 
In more specific embodiments, the targeting agent can be a 
monoclonal antibody or a polyclonal antibody. In particular 
embodiments, the antibody may be a chimeric antibody or 
In some embodiments, the active agents may be non-
covalently sequestered within a cavity, domain or surface of 
a carbon nanomaterial. In some embodiments, the active 
agents may be sequestered from their surrounding environ-
ment by non-covalent association with a carbon nanomate-
rial's solubilizing groups. In more specific embodiments 
where the carbon nanomaterial includes hydrophobic 
domains and hydrophilic domains, the active agent may be 
associated with a hydrophobic domain. In further embodi-
ments, a hydrophobic active agent may be associated with a 
hydrophobic domain of a carbon nanomaterial. In some 
embodiments, this duality of hydrophilic and hydrophobic 
domains can result in the formation of structures resembling 
micelles or liposomes that can further entrap the active 
agents for delivery. 
40 an antibody fragment (e.g., Fab fragment of a monoclonal 
antibody). 
In addition, targeting agents may be associated with 
carbon nanomaterials in various marmers. In some embodi-
ments, targeting agents may be non-covalently associated 
45 with carbon nanomaterials, such as through sequestration, 
adsorption, ionic bonding, dipole-dipole interactions, hydro-
gen bonding, Van der Waals interactions, and other types of 
non-covalent associations. 
In more specific embodiments, targeting agents may be 
50 non-covalently sequestered on a surface of a carbon nano-
material. In some embodiments, targeting agents may be 
covalently associated with carbon nanomaterials. In some 
embodiments, targeting agents may be covalently and non-
In further embodiments, the active agents of the present 
disclosure may be covalently associated with carbon nano-
materials. For instance, in some embodiments, the active 
agents of the present disclosure may be covalently associ-
ated with an active agent through a linker molecule, through 55 
a chemical moiety, or through a direct chemical bond 
between the active agent and the carbon nanomaterial. In 
some embodiments, the active agent may be covalently 
associated with the carbon nanomaterial through a cleavable 
moiety, such as an ester bond or amide bond. In some 
embodiments, the cleavable moiety may be a photo-cleav-
able moiety or a pH sensitive cleavable moiety. Additional 
modes by which active agents may be covalently or non-
covalently associated with carbon nanomaterials can also be 
envisioned. 
covalently associated with carbon nanomaterials. 
In more specific embodiments, the targeting agents of the 
present disclosure may be covalently associated with carbon 
nanomaterials through a linker molecule, through a chemical 
moiety, or through a direct chemical bond between the 
targeting agent and the carbon nanomaterial. In some 
60 embodiments, the targeting agent may be covalently asso-
ciated with the carbon nanomaterial through a cleavable 
moiety, such as an ester bond or amide bond. In some 
embodiments, the cleavable moiety may be a photo-cleav-
able moiety or a pH sensitive cleavable moiety. Additional 
65 modes by which targeting agents may be covalently or 
non-covalently associated with carbon nanomaterials can 
also be envisioned. 
In some embodiments, the therapeutic compositions of 
the present disclosure may include a single active agent. In 
US 9,572,834 B2 
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Markers 
As set forth previously, targeting agents of the present 
disclosure can target various markers related to oxidative 
stress. In some embodiments, such markers may be on a 
surface of a cell. In some embodiments, such markers may 
16 
subject. In some embodiments, the methods and composi-
tions of the present disclosure may be utilized to reduce ROS 
levels in a subject to homeostatic levels, or levels before the 
subject suffered from oxidative stress. In some embodi-
5 ments, the methods and compositions of the present disclo-
sure may be utilized to reduce ROS levels in a subject by 
about 5% to about 50%, by about 50% to about 75%, or by 
about 60% to about 75%. 
be within cells. In some embodiments, such markers may 
include epitopes associated with oxidative stress. In some 
embodiments, such epitopes may be over-expressed or up-
regulated in response to oxidative stress. In some embodi-
ments, such epitopes may be over-expressed or up-regulated 10 
in response to oxidative stress on the surface of a cell, such 
In some embodiments, oxidative stress may be treated by 
attenuating the generation of ROS. In some embodiments, 
oxidative stress may be treated by mitigating the ROS-
induced consumption of endogenous anti-oxidant enzymes. as a cancerous cell. 
In more specific embodiments, the marker is a cell surface 
protein that is over-expressed or up-regulated in response to 
oxidative stress. Non-limiting examples of such markers 
include transferrin receptors, angiotensin receptors, cannabi-
noid receptors, epidermal growth factor receptors, p-selectin 
molecules, adhesion molecules such as intracellular adhe-
sion molecule (ICAM), channel proteins such as the Sul-
foneurea Receptor 1, and combinations thereof. In more 
specific embodiments, such markers may be over-expressed 
or up-regulated on endothelial cells in response to oxidative 
stress, such as traumatic brain injury. In some embodiments, 
suitable markers may also include transport proteins, such as 
transport proteins that can direct therapeutic compositions 
into the central nervous system through the blood brain 
barrier. 
Methods of Treating Oxidative Stress 
Further embodiments of the present disclosure pertain to 
methods of treating oxidative stress in a subject. Such 
methods generally include administering one or more of the 
above-described therapeutic compositions to the subject. 
Oxidative Stress 
Oxidative stress generally refers to an imbalance between 
the production and elimination of reactive oxygen species 
(ROS). Oxidative stress has been implicated in a number of 
diseases, including neurological injury. For instance, oxida-
tive injury to the vasculature is a feature of many conditions, 
including acute neurological injury, such as cerebrovascular 
dysfunction in mild traumatic brain injury (mTBI). 
In some embodiments, the reduction of ROS levels may 
be determined by changes in the intensity of a dye or marker 
15 that is specific for one or more reactive oxygen species. For 
instance, the reduction of ROS levels may be determined in 
some embodiments by changes in di hydroxyethidium 
(DHE) fluorescence intensity. DHE reacts with ROS to form 
2-hydroxyethidium, which possesses red fluorescence when 
20 excited near 480 nm. Thus, the increase in red fluorescence 
can be proportional to the ROS in the sample. 
Furthermore, various concentrations of therapeutic com-
positions may be used to treat oxidative stress. Though 
therapeutic concentration ranges are not limiting, it may be 
25 preferable to administer therapeutic composition concentra-
tions that are not too potent to mitigate normal or necessary 
biological processes. Hence, in some embodiments, it may 
be desirable to choose therapeutic composition concentra-
tion ranges that are suitable for treating oxidative stress with 
30 minimal effects on normal or necessary biological processes. 
Reactive oxygen species that may be targeted by the 
methods and compositions of the present disclosure are also 
not limiting. In some embodiments, the reactive oxygen 
species may include, without limitation, nitric oxides (NO), 
35 superoxides (SO), hydroperoxyls, hydrogen peroxide, oxy-
gen radicals, hydroxyl radicals, organic hydroperoxides, 
alkoxy radicals, peroxy radicals, hypochlorous acids, per-
oxynitrites, and combinations thereof. 
In more specific embodiments, the methods and compo-
40 sitions of the present disclosure may treat oxidative stress by 
restoring or normalizing SO and NO levels in a subject's 
vasculature, such as the cerebral vasculature, or within the 
central nervous system (CNS) itself. In some embodiments, 
such treatments may also improve or enhance a subject's 
The methods and therapeutic compositions of the present 
disclosure may be used to treat oxidative stress that is 
associated with or related to one or more conditions. Such 
conditions may include, without limitation, traumatic brain 
injury, ischemia, anoxic encephalopathy, hypoxic or isch-
emic encephalopathy, cerebrovascular dysfunction, hemor-
rhagic shock, hypoxia, hypotension, Alzheimer's disease, 
Parkinson's disease, multiple sclerosis, amyotrophic lateral 
sclerosis, liver disease, non-alcoholic fatty liver disease, 
diabetes, stroke, inflammation, spinal cord injury, central 50 
nervous system injury or neuropathy, organ transplantation 
(treatment of the organ or the patient), and combinations 
thereof. In some embodiments, the oxidative stress to be 
treated may also be associated with or related to organ 
transplantation. In further embodiments, the oxidative stress 
may be associated with or related to damage to the central 
nervous system, including the spinal cord and surrounding 
tissues. In more specific embodiments, the methods and 
compositions of the present disclosure may be used to treat 
oxidative stress associated with traumatic brain injury or 
non-alcoholic fatty liver disease. 
45 blood flow, such as cerebral blood flow (CBF). In some 
embodiments, the treatments may reduce ROS levels with-
out significant effects in a subject's body weight or feeding 
behavior. 
Subjects 
The therapeutic compos1t10ns of the present disclosure 
may be administered to various subjects. In some embodi-
ments, the subject is a human being, such as a human being 
suffering from oxidative stress. In some embodiments, the 
subject is a human being suffering from TEI-induced oxi-
55 dative stress. In more specific embodiments, the subject may 
be a combat soldier suffering from TBI, or an automotive 
accident victim. In additional embodiments, the subjects 
may be non-human animals, such as mice, rats, other 
rodents, or larger manmials, such as dogs, monkeys, pigs, 
60 cattle and horses. 
Modes of Administration 
Mechanisms of Treating Oxidative Stress 
The methods and compositions of the present disclosure 
can be utilized to treat oxidative stress by various mecha-
nisms. In some embodiments, oxidative stress may be 65 
treated by reducing ROS levels in the subject. This can 
include localized ROS level reduction at a treated site in a 
The therapeutic compositions of the present disclosure 
can also be administered to subjects by various methods. For 
instance, the therapeutic compositions of the present disclo-
sure can be administered by oral administration (including 
gavage ), inhalation, subcutaneous administration (sub-q), 
intravenous administration (I.V.), intraperitoneal administra-
US 9,572,834 B2 
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tion (I.P.), intramuscular administration (I.M.), intrathecal 
injection, and combinations of such modes. In further 
embodiments of the present disclosure, the therapeutic com-
positions of the present disclosure can be administered by 
topical application ( e.g, transderm, ointments, creams, 
salves, eye drops, and the like). Additional modes of admin-
istration can also be envisioned. 
The therapeutic compositions of the present disclosure 
may also be administered in a single dose or multiple doses 
throughout a time period. For instance, in some embodi-
ments, the therapeutic compositions of the present disclo-
sure may be administered to a subject in two separate doses. 
In addition, the therapeutic compositions of the present 
disclosure may be administered to localized sites in a 
subject, such as tissue or vasculature that have suffered from 
oxidative stress. For instance, the therapeutic compositions 
of the present disclosure may be injected directly into the 
brain of a subject that has recently suffered a traumatic brain 
injury, or the spinal colunm of a subject that recently 
suffered an SCI. 
The methods and compositions of the present disclosure 
may also be utilized for targeted treatment. For instance, in 
some embodiments, therapeutic compositions may be asso-
ciated with targeting agents that are specific for endothelial 
cell epitopes that are over-expressed or up-regulated in 
response to oxidative stress (e.g., PEG-HCCs with anti-p-
selectin antibodies). Therefore, upon administration, the 
therapeutic compositions can be directed to vasculature sites 
that have inflicted oxidative stress ( e.g., brain endothelial 
cells and the cerebral vasculature of a subject suffering from 
TBI). 
In various embodiments, the therapeutic compositions of 
the present disclosure may be co-administered with other 
therapies. For instance, in some embodiments, the therapeu-
18 
Suitable formulation materials include, but are not limited 
to: amino acids (e.g., glycine); antimicrobials; antioxidants 
(e.g., ascorbic acid); buffers (e.g., Tris-HCl); bulking agents 
(e.g., mannitol and glycine); chelating agents (e.g., EDTA); 
5 complexing agents ( e.g., hydroxypropyl-beta-cyclodextrin); 
and the like. Additional methods of formulating therapeutic 
compositions can also be envisioned. 
Applications and Advantages 
The therapeutic compositions and methods of the present 
10 disclosure provide numerous applications and advantages. 
For instance, the therapeutic compositions of the present 
disclosure may be used in numerous variations to treat 
oxidative stress associated with numerous conditions, such 
as traumatic brain injury, ischemia, anoxic encephalopathy, 
15 hypoxic or ischemic encephalopathy, cerebrovascular dys-
function, hemorrhagic shock, hypoxia, hypotension, 
Alzheimer's disease, Parkinson's disease, multiple sclerosis, 
amyotrophic lateral sclerosis, liver disease, non-alcoholic 
fatty liver disease, diabetes, stroke, inflammation, spinal 
20 cord injury, central nervous system injury or neuropathy, 
organ transplantation (treatment of the organ or the patient) 
and combinations thereof. In some embodiments, the meth-
ods and compositions of the present disclosure may be used 
to treat oxidative stress induced by stroke, hypoxia, organ 
25 transplantation, injury to the neurovascular unit ( e.g, TBI), 
hypotension, resuscitation, blood reperfusion, and other 
similar conditions. 
In more specific embodiments, the methods and compo-
sitions of the present disclosure may be used to treat 
30 cerebrovascular dysfunction following TBI. As set forth in 
more detail in the Examples below, such methods may be 
used to rapidly restore cerebral blood flow (CBF) in TBI 
patients. As also set forth in more detail in the Examples 
below, the methods and compositions of the present disclo-
tic compositions of the present disclosure may be co-
administered along with anti-cancer drugs. This could be 
especially helpful in cases where the anti-cancer drug causes 
neuropathy, and where the neuropathy could be mitigated by 
the anti-oxidant properties of the carrier composition ( e.g., 
PEG-HCCs ). Other modes of co-administration can also be 40 
envisioned. 
35 sure may be used to treat oxidative stress associated with 
non-alcoholic Fatty liver disease (NALFD). The methods 
and compositions of the present disclosure can also be used 
to treat oxidative stress associated with Alzheimer's disease, 
multiple sclerosis, and ALS. 
In addition, the methods and compositions of the present 
disclosure provide numerous advantages in treating oxida-
tive stress. For instance, the methods and compositions of 
the present disclosure may significantly reduce ROS levels 
in subjects suffering from oxidative stress with minimal side 
Methods of Formulating Therapeutic Compositions 
Additional embodiments of the present disclosure gener-
ally pertain to methods of making therapeutic compositions 
of the present disclosure. Such methods generally comprise: 45 effects and toxicities. Furthermore, due to the anti-oxidative 
nature of the carbon nanomaterials, the methods and com-
positions of the present disclosure can be more effective than 
current methods in treating oxidative stress. 
(1) associating a nanomaterial with one or more active 
agents; and (2) associating one or more targeting agents with 
the nanomaterial. In some embodiments, one or more of the 
above-mentioned associations may occur non-covalently, 
such as by sequestration, adsorption, ionic bonding, dipole- 50 
dipole interactions, hydrogen bonding, Van der Waals inter-
actions, and other types of non-covalent interactions. In 
further embodiments, one or more of the associations may 
occur by covalent bonding. 
In various embodiments, the aforementioned associations 55 
may occur simultaneously or sequentially. In some embodi-
ments, the associations may occur by mixing a nanomaterial 
with one or more active agents and targeting agents. 
Therapeutic compositions of the present disclosure can 
also be formulated in conventional manners. In some 60 
embodiments, the formulation may also utilize one or more 
physiologically acceptable carriers or excipients. The phar-
maceutical compositions can also include formulation mate-
rials for modifying, maintaining, or preserving various con-
ditions, including pH, osmolarity, viscosity, clarity, color, 65 
isotonicity, odor, sterility, stability, rate of dissolution or 
release, and/or adsorption or penetration of the composition. 
Additional Embodiments 
Reference will now be made to more specific embodi-
ments of the present disclosure and experimental results that 
provide support for such embodiments. However, Appli-
cants note that the disclosure below is for illustrative pur-
poses and is not intended to limit the scope of the claimed 
subject matter in any way. 
EXAMPLE 1 
PEG-HCCs for Treatment of Oxidative Stress 
Associated with mTBI 
Example 1 pertains to the design of PEG-HCCs for 
targeted therapy of cerebrovascular dysfunction in mild 
traumatic brain injury. TBI involves the elaboration of 
oxidative stress. Currently, there is no clinically effective 
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antioxidant treatment for these pathologies. Here, Appli-
cants report that PEG-HCCs possess innate antioxidant 
activity and can be rapidly targeted via an antibody to the 
p-selectin antigen in a model of injured cultured brain 
endothelial cells. One immediate application of this therapy 5 
is to vascular dysfunction that accompanies TBI and wors-
ens outcome in the face of systemic hypotension. 
Oxidative stress and vascular dysfunction is a prominent 
feature of TBI, especially when accompanied by secondary 
insults, such as hemorrhagic hypotension. Cerebrovascular 10 
dysfunction is evident even in mild TBI (mTBI), and if 
complicated by hypotension, causes both structural lesions 
and behavioral dysfunction. In the case of an acute injury, 
there is both an acute elaboration of oxidative radicals and 
an extended period of oxidative stress as the initial injury 15 
sets off a cascade that can last for days. Consequently, 
antioxidant therapies have been investigated for treating 
TBI. 
Extensive research has explored using small molecule 
antioxidants, such as PBN and tirilazad mesylate, or stabi-
lized enzymes, such as PEG-SOD, to combat oxidative 
stress. Unfortunately, none of these potential therapies has 
shown efficacy in clinical trials, and there are no Food and 
Drug Administration-approved antioxidant therapies for 
20 
these conditions. 25 
The generation of oxidative radicals is rapid following 
TBI. Secondary insults such as hypotension, a major con-
tributor to poor outcome in TBI, are additional sources of 
oxidative radical generation with several bursts of superox-
ide documented throughout the course ofTBI and hypoten- 30 
sion and reperfusion. Moreover, Applicants' previous work 
has shown that PEG-SOD has only small and transient 
effects. Hence, there is a need to find new classes of 
biologically compatible antioxidants. 
Here, Applicants show that PEG-HCCs possess antioxi- 35 
dant activity potent enough to reduce oxidative stress in 
vitro and can be targeted to a model of injured brain 
endothelial cells expressing p-selectin antigen. P-selectin 
expression is increased in brain endothelial cells following 
traumatic brain injury, and possibly systemically depending 40 
on the trauma mechanism. These results suggest that tar-
geted PEG-HCCs are potential therapeutics for oxidative 
stress-induced cerebrovacular dysfunction from TBI. 
EXAMPLE IA 45 
Materials and Methods 
Preparation of PEG-HCCs 
PEG-HCCs were prepared as previously described and 50 
sterile filtered using a 0.20 µm pore size membrane. ACS 
Nano. 2010 (4): 4621-4636. Preliminary toxicity and bio-
distribution studies indicate that these nanoparticles are not 
acutely toxic. These PEG-HCCs can be loaded with hydro-
phobic drugs, and when mixed with an antibody, a nonco- 55 
valent formulation capable of targeted drug delivery in vitro 
20 
disodium ethylenediamine tetraacetate (EDTA, cat # 
E4884), as obtained from Fisher Scientific. Deferoxamine 
mesylate salt (DFO, cat#D9533) was obtained from Sigma-
Aldrich. 
ORAC Assay 
The following solutions were prepared daily: phosphate 
buffer at pH 7.4 (PBS, 75 mM), fluorescein sodium salt (0.1 
and 0.2 µM), a,a'-azodiisobutyramidine dihydrochloride 
(AAPH, 0.15 M), racemic 6-hydroxy-2,5,7,8-tettramethyl-
chromate-2-carboxilic acid (trolox, 400 µM). The experi-
ment was carried out in a 96-well plate and each sample was 
analyzed by triplicate, as shown in Table 1. 
TABLE 1 
ORAC Assay Design. 
Table 1. ORAC Assay Design 
1st step 2nd step 
Assay 120 µL of Fluorescein 20 µL of 60 µL of AAPH 
Sample 
Control 1 120 µL of Fluorescein 20 µL of 60 µL of PBS 
(no AAPH) Sample 
Control 2 120 µL of PBS 20 µL of 60 µL of AAPH 
(no Fluorescein) Sample 
Trolox and phosphate buffer (blank) were run as samples. At least 3 standards of trolox 
were run for the calibration curve 
After the addition of the fluorescent probe or PBS and 
sample (ls' step) to the assigned wells, the plate was incu-
bated at 37° C. for 15 min in a TECAN plate reader. Then, 
the ice-cold AAPH or PBS was added (rd step) and the 
fluorescent intensity at 530 nm ( 485 nm excitation) was 
measured every minute for 2 h. Data were analyzed as 
follows: control 2 (background) was subtracted from the 
assay and control 1. The assay well results were divided by 
the control 1 and the area under the curve (AUC) was 
determined by equation 1. 
fl f2 f3 fl 
AUC= 1+-+- +- + ... +-JO JO JO JO 
(Eq. 1) 
Trolox mass equivalents (TME) were determined by 
equation 2. 
TME= AUCsample -AUCstank X TroloXmas~mg) 
AUCrrolox -AUCstank Samplemas.5(.mg) 
(Eq. 2) 
Benzoate Hydroxylation 
This assay is based on the hydroxylation of benzoate 
when exposed to iron and H20 2 , producing the fluorescent 
compounds 2,3,4-trihydroxybenzoate (308 nm excitation 
and 410 nm emission) with the major products 2-hydroxy-
benzoic acid salt or salicylic acid salt at pH 7.4. In brief, the 
following solutions were freshly prepared before each run 
according to reported procedures: benzoic acid (3 mM, 
recrystallized from hot water), FeCl3 (1.80 mM), FeS04 
is formed. Based on the antibody/PEG-HCCs interaction 
previously reported, Applicants mixed p-selectin antibody 
with the PEG-HCCs and evaluated the targeting properties 
of the system. 60 (1.80 mM), methoxypolyethylene glycol amine polymer 
(PEG MW 5,000, 0.02 mg/mL) and PEG-HCCs (0.02 
mg/mL). EDTA (0.60 mM) and DFO (0.60 mM) were used 
as the positive and negative control, respectively. The ben-
It has been found that iron forms deposits in patients with 
mTBI. In order to explore the behavior of the iron when 
combined with PEG-HCCs, Applicants ran the following 
iron chelator assays: benzoate hydroxylation and ascorbate 
oxidation. Ascorbic acid (cat# AC40147), benzoic acid (cat 65 
# AC22180), iron(II) sulfate heptahydrate (cat# AC42373), 
iron(III) chloride hexahydrate ( cat # AC21709), and the 
zoic acid was incubated at room temperature for 1 h in the 
phosphate buffer (pH 7.4) with 5 mM ofH20 2 and the ferric 
or ferrous iron salt, in the presence of one of the controls or 
the PEG-HCCs. The reaction was started by the addition of 
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any the iron salts and kept in dark. Salicylate was used to 
determine the quenching effect of the materials. 
Ascorbate Oxidation 
This assay was performed in a similar way to that 
described previously. Rad. Res. Comms. 1985 (1):349-353; 5 
J Biochem Biophys Methods 1988 (16):27-40; Radiat Res. 
1996 (145):532-541. Briefly, the following solutions were 
prepared prior to each experiment: ascorbic acid (0.1 mM), 
FeCl3 (0.60 mM), potassium phosphate buffer (50 mM, pH 
7.4, cleaned with Chelex resin), EDTA (0.02 mg/mL previ- 10 
ously recrystallized three times from hot water), DFO (0.02 
mg/mL), and PEG-HCCs (0.02 mg/mL). The ascorbate 
absorbance at 265 nm was measured after 1, 5 and 30 min 
using a TECAN plate reader. 
Cell Culture 
Murine brain endothelioma (bEnd.3, CRL 2299, ATCC, 
Manassas, Va.) were cultured in DMEM-F12 (50:50) with 4 
mM L-glutamine media, supplemented with 10% fetal 
bovine serum (both from HyClone) and 1 % Pen Strep 
( + 10,000 u/mL penicillin/+ 10,000 µg/mL streptomycin, 
from GIBCO). During the second week, between the 4th and 
6th passage, cell experiments were performed. 
P-Selectin Targeting 
bEnd.3 cells were grown on glass covers to 60-70% 
confluence in 6 well plates. P-selectin-targeted PEG-HCCs 
(ps/PEG-HCCs) were synthesized by adding 0.01 µg anti-
p-selectin antibody (Santa Cruz Biotechnology Inc., Santa 
Cruz, Calif.) to 0.49 µg PEG-HCCs and incubating at RT for 
15 
20 
25 
1 h. The antibody possesses hydrophilic and hydrophobic 30 
domains that allow the nanomaterial to sequester it. The 
bEnd.3 cells were treated with histamine (20 µM) to induce 
p-selectin expression or lxPBS (histamine diluent) as a 
control. (McEver et al., 1989). After a 15 min incubation at 35 
37° C., the cells were treated with vehicle (lxPBS), PEG-
HCCs (0.49 µg), or ps/PEG-HCCs. Cells were incubated for 
15 min and then washed twice and fixed with methanol. 
Cells were washed and stained with anti-PEG (Epitomics, 
Burlingame, Calif.) and anti-p-selectin antibodies (Santa 
Cruz Biotechnology Inc, Santa Cruz, Calif.). After washing, 
cells were probed with fluorescent secondary antibodies to 
the anti-PEG and anti-p-selectin antibodies (Invitrogen, 
Carlsbad, Calif.). Glass covers were mounted on slides and 
fluorescent images were captured on an epifluorescent 
microscope. 
Intracellular Superoxide Cell Culture Model 
40 
45 
bEnd.3 cells were cultured to 50-80% confluence in 6 well 
plates in 2 mL of culture media. The cells were treated with 
vehicle (lxPBS), PEG-HCCs, ps/PEG-HCCs, or p-selectin 50 
antibody alone (same concentration as found in ps/PEG-
HCCs ). After 15 min, the cells were treated with 10 µL of 2 
mM Antimycin A (AntA) or 10 µL ethanol ( control). AntA 
has been shown to induce intracellular superoxide radical 
production. (Han et al., 2008). The cells were incubated at 55 
37° C. for 40 min, at which point 2 µL of 10 mM dihy-
droethidine (DHE) (Zhao et al. 2005). (in 50%/50% DMSO/ 
lxPBS) was added to wells or 50%/50% DMSO/lxPBS 
( control). DHE reacts with ROS to form 2-hydroxyethidium, 
which possesses red fluorescence when excited near 480 nm; 60 
thus, the increase in red fluorescence is proportional to the 
ROS in the sample. (Zhao et al., 2005). The cells were then 
placed on ice, trypsinized, and washed twice. Cells were 
subsequently counted and stained with SytoxRed (viability 
stain). 10,000 cells were analyzed per treatment group using 65 
the TXRED channel (DHE) and SytoxRed to assess cell 
viability. 
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EXAMPLE 1B 
Anti-Oxidant Activity of PEG-HCCs 
The antioxidant capacity of the PEG-HCCs was compared 
by the ORAC assay to known antioxidants vitamin C, caffeic 
acid, and catechin. ORAC measures antioxidant capacity by 
the ability of a substance to inhibit the loss of fluorescence 
caused by the oxidation of a fluorescent dye by peroxyl 
radicals formed during the thermal decomposition of the 
AAPH without the assistance of any metal. The linear 
relationship between the net area and antioxidant concen-
tration was evaluated by using a set of trolox and PEG-
HCCs standards. See FIGS. 2 and 8-9. Table 2 summarizes 
the correlation coefficient, slope, and intercept of the trolox 
standard curves obtained in each run. 
Run 
2 
3 
4 
TABLE 2 
Sunnnary of Trolox Calibration curve for each 
nm related to known antioxidants evaluation 
(Y(Net. AUC) ~a+ b X(mg/mL)). 
R2 Slope (b) Intercept (a) Observations 
0.9982 424.9 ± 18.1 0.677 ± 0.599 3 standards 
0.9991 399.9 ± 12.1 -0.325 ± 0.399 3 standards 
0.9991 431.0 ± 32.5 3.364 ± 0.439 3 standards 
0.9998 387.1 ± 5.4 2.980 ± 0.179 3 standards 
Average 0.9990 410.7 ± 20.7 1.674 ± 1.784 
Accepted R2 >0.9900. Slope and intercept errors calculated at 95% confidence 
The assay was consistent for all concentrations tested. For 
comparison and TME calculations, the concentrations of 
vitamin C, caffeic acid, catechin, trolox, and PEG-HCCs 
were kept constant at 1.6 µg/mL. See FIG. 2A and Table 3. 
Run 
2 
3 
4 
TABLE 3 
THE corresponding to tbe known antioxidants evaluation. The 
concentration of each compound was tbe same (1.61. tg/mL). 
Vitamin C Caffeic Acid Catechin Trolox PEG-HCC 
1.02 7.04 5.68 1.00 2.96 
0.78 9.68 7.58 1.00 3.73 
0.30 5.38 4.25 1.00 2.07 
0.22 6.43 4.78 1.00 2.24 
Average 0.58 7.13 5.57 1.00 2.75 
SD 0.38 1.83 1.46 n.a 0.76 
SE 0.19 0.92 0.73 n.a 0.38 
According to these results, PEG-HCCs showed higher 
antioxidant capacity than vitamin C, but lower than catechin 
and caffeic acid. See FIG. 28. This range of antioxidant 
potential demonstrates that the PEG-HCCs possess biologi-
cally relevant antioxidant capacity. Without being bound by 
theory, Applicants envision that this anti-oxidant property is 
due to the conjugated domains in the carbon core. When 
these domains receive two RO• species, two carbon-carbon 
pi-bonds could be lost but two new C---0 sigma bonds and 
one new C----C pi bond could be formed without any radical 
species remaining. See FIG. lB. 
EXAMPLE IC 
The Role of Chelation in PEG-HCC Antioxidant 
Activity 
Iron accumulation in the pathology of TBI has been 
reported for mice and humans based on magnetic resonance 
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imaging. It is known that Fe+2 and Fe+3 form lipid alkoxy 
radical and peroxyl radicals respectively, which induced the 
production of the neurotoxic aldehydes. Therefore, it is 
important to determine if the nanoparticles stimulate the iron 
redox cycle (similar to EDTA) or inhibit it (similar to DFO). 5 
In order to assess this property, chelation assays were 
performed. 
Benzoate Hydroxylation Assay 
The iron chelating assay was used to evaluate the anti-
oxidant capacity of PEG-HCCs when it is exposed to 10 
hydroxyl radicals produced by the reaction between iron and 
H2 0 2 . In this assay, Applicants monitored the oxidation of 
benzoate to salicylate by hydroxyl radicals produced by the 
Fenton reaction. To ensure that this measurement would be 
robust, sodium salicylate (SA) was mixed with PEG or 15 
PEG-HCCs every time that the experiment was run, in order 
to estimate how the fluorescence intensity was affected by 
the nanomaterial or the polymer, and then Applicants pro-
ceeded to correct it. See FIG. 3A. In general, it was observed 
that PEG-HCCs quench about-20% of the fluorescence and 20 
the PEG can enhance the fluorescence up to -10%. In the 
actual assay, EDTA and DFO were included as positive and 
negative controls, respectively. PEG-HCCs decreased the 
hydroxylation process as well as DFO in comparison to the 
case in which no chelating agent was added for both iron 25 
systems. See FIG. 38. Both PEG-HCCs and PEG reduced 
the hydroxylation ofbenzoic acid when the highest concen-
tration of Fe+2 was used. Without being bound by theory, 
Applicants envision that this could be due to the radical 
scavenger capacity of the carbon core in the PEG-HCCs 30 
(FIG. lB), the degradation of the polymer chains as previ-
ously reported (Proc. Nat. Acad. Sci. USA, 1998 (95): 
10373-10377), or both. Applicants also observed that the 
Iron/PEG-HCCs systems do not induce the Fenton reaction. 
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were treated with histamine, which is known to rapidly 
induce the expression of p-selectin. PEG-HCCs were tar-
geted to p-selectin. In endothelial cells, p-selectin, a cell 
adhesion molecule, is involved in recruiting leukocytes to 
sites of inflanimation and injury. P-selectin is rapidly 
expressed on endothelial cells following activation by his-
tamine. 
In this experiment, Applicants treated cells with histamine 
or lxPBS to induce p-selectin expression. See FIG. 5. After 
15 min, the cells were treated with lxPBS, PEG-HCCs, or 
PEG-HCCs associated with anti-p-selectin antibodies (ps/ 
PEG-HCCs). The cells were incubated for another 15 min 
and after washing and fixing, they were stained with fluo-
rescent antibodies for the presence of PEG to detect PEG-
HCCs using an anti-PEG antibody (green), anti-p-selectin 
antibody(red) to detect p-selectin, and DAPI (nuclear stain; 
blue). In the cells that are not stimulated by histamine, there 
is little binding apparent with the p-selectin targeted PEG-
HCCs. However, there was a dramatic increase in the 
binding of ps/PEG-HCCs to cells after stimulation by his-
tamine. See FIG. 6, bottom panel. This experiment demon-
strates enhanced binding of the targeted PEG-HCCs to 
endothelial cells in a model that induces expression of a 
protein, p-selectin. 
Applicants also evaluated whether applying the targeted 
p-selectin antibody to the PEG-HCC would reduce its anti-
oxidant ability. Applicants tested the protective capacity of 
the nanoparticles by stressing the cells with AntA and 
determining the effectiveness of the native or antibody 
bound PEG-HCCs at reducing levels of oxidative radicals. 
The level of oxidative stress was measured by DHE fluo-
rescence. An increase in fluorescence is proportional to 
oxidative stress and is roughly proportional to superoxide 
levels, although not specific under all conditions. In this 
Ascorbic Acid Assay 
Ascorbic acid is able to serve as a donor antioxidant in 
free radical-mediated oxidative processes. But it is also able 
35 study, Applicants replicated the ability of the PEG-HCCs to 
reduce DHE fluorescence, even when applied after the 
AntA, and found that ps/PEG-HCCs reduced the level of 
DHE fluorescence to comparable levels as non-antibody to reduce redox-active metals such as copper and iron, 
thereby increasing the oxidant properties of those metals. In 
general, at low concentrations, ascorbic acid is prone to be 40 
a pro-oxidant and at high concentrations serves as an anti-
oxidant. In this assay, the oxidation of ascorbic acid by Fe3+ 
is monitored in the presence or absence of various sub-
stances. EDTA again enhanced the oxidative activity of the 
Fe+3 while DFO inhibited it. See FIG. 4. 
Applicants also tested PEG-HCCs in this system to deter-
mine if their antioxidant capacity could be due to interac-
tions with trace iron content, and if there is such an inter-
action, the oxidation of the ascorbic acid should be inhibited. 
Applicants found that in this system, PEG-HCCs function as 
potent oxidants, regardless of the presence or absence of 
Fe3+. See FIG. 4. PEG-HCCs and ascorbic acid show similar 
pro-oxidant and antioxidant behavior. A difference is that for 
PEG-HCCs, no metal participation is required. 
EXAMPLE ID 
Targeted Binding of PEG-HCCs to Brain 
Endothelial Cells 
Next, Applicants evaluated if PEG-HCCs could be tar-
geted to cultured brain endothelial cells, and if they could 
also alleviate oxidative stress in a biological system. A brain 
endothelial cell line was chosen because endothelial dys-
function is apparent even after mTBI. In the case of mTBI, 
there is minimal detectable brain injury and functional 
deficits unless hypotension is superimposed. bEnd.3 cells 
bound PEG-HCCs, and to background (DHE). See FIG. 7. 
By comparison, p-selectin antibody by itself had no signifi-
cant effect on DHE fluorescence. 
Remarks 
The results in Example 1 indicate that PEG-HCCs possess 
biologically relevant antioxidant capacity. Furthermore, the 
45 results indicate that the mechanism may not involve chela-
tion. PEG-HCCs were effective in vitro following adminis-
tration of a mitochondrial toxin that induces oxidative stress. 
PEG-HCCs could also be readily targeted to oxidatively 
stressed brain endothelial cells. When functionalized for 
50 targeting, PEG-HCCs retained the ability to alleviate oxi-
dative stress in cultured brain endothelial cells. Overall, 
these results suggest that targeted PEG-HCCs are potential 
therapeutics for the cerebrovascular dysfunction from 
mTBI, and the results open additional possibilities for tar-
55 geting a variety of pathological processes. 
Because of the deleterious effects of loss of cerebrovas-
cular responsiveness, even in mild injuries, a therapy that 
mitigates oxidative injury to endothelial cells should hold 
promise for the improvement of outcome following mTBI. 
60 Furthermore, because there is a major burst of superoxide 
radical at the time of resuscitation following TBI and 
hemorrhagic hypotension; treatment at the time of resusci-
tation may provide a clinically realistic time point that can 
address at least one pathological event in the care of the TBI 
65 patient. 
In addition, targeting the PEG-HCC using a p-selectin 
antibody demonstrated a more rapid binding to stressed 
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b.End3 cells. This characteristic may have advantages as a 
therapeutic agent with enhanced binding to molecules 
expressed at the site of injury. There are many potential such 
targets, but p-selectin appears particularly promising as 
there is some added therapeutic benefit in experimental TBI 5 
of the antibody itself, potentially in addition to the antioxi-
dant ability of the PEG-HCCs. 
EXAMPLE 2 
Use of PEG-HCCs to Treat Oxidative Stress 
Associated with TBI 
10 
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there is a concomitant normalization of both SO and the 
vasodilator, nitric oxide (NO), levels. 
EXAMPLE 2A 
Effects of PEG-HCCs on b.End3 Cells 
By confocal microscopy studies, Applicants confirmed 
that PEG-HCCs are rapidly internalized by b.End3 cells. See 
FIGS. 10-11. Next, a series ofin vitro studies showed that 
when oxidative stress was induced in b.End.3 cells by 
treatment with the mitochondrial toxin, antimycin A, the 
Example 2 provides additional support that PEG-HCCs 
can be used to treat oxidative stress associated with TBI. 
Specifically, Example 2 provides data indicating that PEG-
HCCs can be used to improve cerebrovascular dysfunction 
following TBI. Applicants demonstrate in this Example that 
PEG-HCCs are effective antioxidants in cell culture and 
rapidly restore cerebral blood flow (CBF) in a traumatic 
brain injury/hypotension/resuscitation rat model when 
administered during resuscitation. 
15 intracellular oxidative stress could be reduced in a dose-
dependent manner by treatment with PEG-HCCs. See FIG. 
12. The amount of oxidative radical expression was mea-
sured as a proportion of DHE fluorescence. PEG-HCC 
treatment was effective even 10 min after toxin exposure, 
20 while neither PEG-SOD nor PBN was effective in the 
post-toxin-treated cells. The latter two traditional antioxi-
dants were only effective pre-toxin exposure, and then only 
at a 10 to 30x higher dose. See FIG. 12A. Furthermore, at 
higher doses of antimycin A where significant cell death 
could be induced, post-treatment with PEG-HCCs was able 
to restore cell viability to more than 65% of baseline. 
However, no protective effect from post-treatment with 
either PEG-SOD or PBN could be observed. See FIG. l2B. 
Injury to the neurovasculature is a feature of brain injury 
and must be addressed to maximize opportunity for 25 
improvement. Cerebrovascular dysfunction, manifested by 
reduction in cerebral blood flow (CBF), is a key factor that 
worsens outcome after traumatic brain injury (TBI), most 
notably under conditions of hypotension. Applicants report 
here that PEG-HCCs rapidly restore CBF in a mild TBI/ 
hypotension/resuscitation rat model when administered dur-
ing resuscitation-a clinically relevant time point. Along 
with restoration of CBF, there is a concomitant normaliza-
tion of superoxide and nitric oxide levels. Given the role of 
These studies demonstrate the efficacy of the PEG-HCCs 
30 to eliminate ROS that would otherwise have resulted in cell 
35 poor CBF in determining outcome, this finding is of major 
importance for improving patient health under clinically 
relevant conditions during resuscitative care. In addition, the 
findings have direct implications for the current TBI/hy-
potension war-fighter victims in the Afghanistan and Middle 40 
East theaters. The results also have relevancy in other related 
acute circumstances such as stroke and organ transplanta-
tion. 
death. Additional in vitro control experiments in bEnd.3 
cells indicated that the PEG-HCCs do not quench NO 
sensitive fluorescence of DAF-2 associated with spontane-
ous NO release from these cells. See FIGS. 13-14. 
EXAMPLE 28 
In Vivo Effects of PEG-HCCs 
PEG-HCCs were next evaluated in vivo. The TBI model 
used in this Example aimed to mimic the common clinical 
situation in which TBI is accompanied by a systemic injury Injury to the neurovascular unit is recognized as a major 
determinant of patient outcome, and it has been hypoth-
esized that therapies that do not address that injury are 
unlikely to promote recovery. In the case of traumatic brain 
injury (TBI), damage to the neurovascular unit is manifested 
under conditions of abnormally low blood pressure, known 
as hypotension, by loss of cerebral autoregulation and poor 
reperfusion upon resuscitation. These events contribute to 
the clinical finding that hypotension, even in mild TBI, 
predicts poor outcome. 
45 resulting in hypotension. There is minimal evidence of either 
behavioral or histological injury with either TBI or hypoten-
sion alone, but with the superimposition of hemorrhagic 
hypotension and subsequent resuscitation, there is marked 
expansion of lesion size and behavioral impairment. See 
Elevated levels of reactive oxygen species (ROS), such as 
superoxide (SO), are found in the vasculature and have been 
shown to mediate loss of autoregulatory tone. Along with 
spikes of ROS following trauma, continued damaging spikes 
50 FIG. 15. Reperfusion CBF was reduced in proportion to the 
increase in injury, supporting the hypothesis that this is 
primarily a vasculature injury. The loss of autoregulation 
and poor reperfusion originating in the brain endothelium 
contribute to injury, even in the setting of mild TBI. This 
55 highlights that while the blood-brain barrier becomes com-
promised following mild TBI, thereby allowing access of 
agents such as PEG-HCCs to the brain itself, the major 
treatable injury in the TBI and secondary injury paradigm is 
to the brain endothelium. in the level of ROS are observed upon subsequent blood 
reinfusion during resuscitation. Hence, in an effort to stabi- 60 
lize the patient, furtherance of oxidative damage ensues. 
However, blood reinfusion also provides an opportunity to 
intervene at a clinically realistic time point. In this report, 
Applicants demonstrate that PEG-HCCs, which are nontoxic 
carbon particles, rapidly restore cerebral blood flow (CBF) 65 
in a TBI/hypotension/resuscitation rat model when admin-
istered during resuscitation. Along with restoration of CBF, 
Using the above-mentioned TBI/hypotension/resuscita-
tion rat model, treatment followed the field situation as 
follows. 50 min after the injury and loss of blood, phosphate 
buffered saline (PBS) was administered in an ambulance 
"prehospital" phase. Next, after further delay of 30 min, 
definitive "hospital" care consisted of therapy administra-
tion, oxygenation and blood infusion. The model is outlined 
in Table 4 and described below. 
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TABLE 4 
Rat Injury Model for Testing the Effects of PEG-HCCs 
Phase 1 Phase 2 Phase 3 
Injury and Prehospital- Definitive- Phase 4 
hemorrhage ambulance hospital Test outcome 
(50 min) (30 min) (30 min) (6 h) 
Ventilate (air) Ventilate (air) Give drug Ventilate 0-6 h Monitor 
Mild TB! Initial with 100% oxygen cerebral 
Withdraw blood resuscitation- Reinfuse blood hemodynarnics 
to MAP saline MAP" Saline to MAP " 6 h Determine 
40 mm Hg 50 mm Hg 60 mmHg SO and 
NO levels 
5 
10 
In Phase 1, Long Evans rats (250 to 300 g) underwent 15 
sham injury or mild cortical compression injury TBI (3 mis, 
2.5 mm deformation, Table 5) plus hemorrhagic hypotension 
produced by controlled blood withdrawal to reach a mean 
arterial blood pressure (MAP) of 40 mm Hg. This occurred 
in a decelerating protocol to mimic trauma blood loss. 
TABLE 5 
TB! impact characteristics and rat weights 
Statistics (repeated measures ANOVA) 
Vehicle PEG-HCCs 
Rat weight (grams) 287.1 ± 27.0 279.0 ± 16.0 
Mean± SD 
Impact characteristics 
Velocity mis 3.29 ± 0.41 3.25 ± 0.49 
Duration ms 79.0 ± 8.9 80.8 ± 5.7 
p-value 
0.3955 
0.8388 
0.5733 
In order to simulate field resuscitation and ambulance 
20 
25 
30 
28 
FIG. 16B shows a qualitatively similar effect in the 
peri-traumatic region, with rCBF returning to baseline in the 
PEG-HCC-treated group, while remaining depressed in the 
vehicle-treated group. No effect on rCBF of either group in 
the contralateral cortex (FIG. 16C) indicates that the out-
comes seen in the lesion and peri-lesional regions were not 
artifactual. Additional experiments in a model to simulate 
linear flow show that there was no effect of PEG-HCCs on 
the LDF signal used to measure CBF, nor did the PEG-HCCs 
influence systemic blood pressure or physiological vari-
ables. See FIG. 17 and Table 6. 
TABLE 6 
Arterial blood gases in the TB! and hypotension model at baseline, 
end of hypotension and during the hospital phase. 
Arterial blood gases 
(mean± SD) Vehicle 
Baseline pH 7.44 ± 0.06 
pC02 41.46 ± 4.07 
p02 300.9 ± 80.7 
Hypotension pH 7.39 ± 0.01 
pC02 41.85 ± 1.06 
p02 139.1 ± 48.7 
Hospital pH 7.29 ± 0.11 
pC02 41.77 ± 1.99 
p02 249.9 ± 100.3 
pC02 is the partial pressure of CO2 
p02 is the partial pressure of 0 2 
Statistics: Repeated measures ANOVA 
PEG-HCCs p-value 
7.45 ± 0.07 0.775 
39.08 ± 7.4 0.8425 
309.5 ± 87.6 0.9144 
7.30 ± 0.05 
47.83 ± 4.99 
101.2 ± 36.4 
7.40 ± 0.09 
37.73 ± 9.44 
295.9 ± 85.7 
These results demonstrate that in a model ofTBI/hypoten-
sion/resuscitation, the PEG-HCCs rapidly restore the cere-
bral perfusion and that the PEG-HCCs were directly improv-
ing CBF in the injured area. 
Furthermore, as shown in FIG. 18, the injection of PEG-
HCCs significantly reduced vascular SO levels, underscor-
ing that this is primarily a vasculature injury. See FIGS. 
18A-C. Concomitantly, treatment with PEG-HCCs com-
transport (Phase 2), the rats received an i.v. of Lactated 35 
Ringer's solution for initial resuscitation. Next, hospital care 
(Phase 3) was simulated by administering a single dose of 
PEG-HCCs (2 mg/kg) or a diluent vehicle, phosphate buff-
ered saline (PBS), via a 5 min i.v. tail vein administration. 
This was followed by oxygenation and blood reinfusion. 
Beginning with Phase 1, there was extensive physiological 
monitoring included MAP, arterial blood gases, intracranial 
pressure and non-invasive spatial brain perfusion using laser 
Doppler flowmetry (LDF, Periscan). 
40 pletely restored vascular NO levels. See FIGS. 18D-F. This 
duality of modes in the resuscitative phase of treatment, 
specifically decreasing SO and normalizing NO, is unpre-
dictable in such injury models. 
In summary, this Example illustrated that PEG-HCCs are 
As illustrated in FIG. 16, PEG-HCCs restored cerebral 
perfusion and normalized the oxidative radical profile. Rats 
received a single dose of PEG-HCCs (2 mg/kg) or PBS at 
the beginning of the blood resuscitation (Phase 3). CBF was 
measured for 6 h from the cortical surface with LDF (Phases 
45 non-toxic and anti-oxidative particle-based drugs that have 
efficacy at the neurovascular level in restoring CBF after 
mild TBI. The results shown for restoring CBF while 
normalizing SO and NO levels primarily in the cerebral 
vasculature are suggestive of a treatment that could vastly 
50 improve the recovery and long-term neurological prognosis 
for traumatized patients. Furthermore, the results indicate 
that PEG-HCCs could also be used for other acute disorders, 
such as stroke in which reperfusion-based ROS release is 
associated with extension and propagation of injury. 
3 and 4). Just before the 6 h mark, rats were injected with 
dyes for SO ( dihydroethidium, DHE) and NO ( diaminofluo-
rescein diacetate, DAF-2DA) detection, and perfusion fixed. 
Systemic injection of these dyes and a short circulation time 
was able to identify vascular expression of these radicals. 
LDF-relative CBF (rCBF) is shown in the series of FIGS. 55 
16A-C. EXAMPLE 2C 
Double Dosing of PEG-HCCs in Treating CBF 
As set forth in the aforementioned Examples, Applicants 
have shown that a single dose of PEG-HCCs can improve 
CBF in a rat model of mTBI and hemorrhagic shock when 
administered 80 minutes after TBI. The length of the effect 
on CBF correlated well with the half life of the PEG-HCCs 
FIG. 16A illustrates changes in rCBF in the region of the 
traumatic injury. Hypotension following TBI significantly 
reduced rCBF. In the vehicle-treated TBI group, rCBF was 
only partially restored by reinfusion of shed blood while 60 
rCBF returned rapidly to baseline levels following admin-
istration of the PEG-HCCs and blood. The duration of the 
PEG-HCC effect was from 2 h to 3 h, at which time both 
groups showed a decline in rCBF. This duration of treatment 
effect is consistent with the 2 h to 3 h blood half-life of 
PEG-HCCs and also consistent with the prolonged anesthe-
65 in the bloodstream (2-3 hours). This Example aims to 
determine whether a second dose of PEG-HCCs would 
sia time. sustain this effect. 
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As summarized in FIG. 19, data comparing a single dose 
of PEG-HCCs and two doses of PEG-HCCs (administered 2 
hours apart) indicate that a second dose of PEG-HCCs 
sustains CBF. Laser Doppler flowmetry (LDF) was used to 
measure CBF. All CBF values were normalized to the 5 
baseline CBF value for each rat (relative CBF). The relative 
CBF was maintained in the injured brain at the end of the 
monitoring period (6 h post TBI) with a second dose of 
PEG-HCCs (91.9±29.5 relative CBF in 2 dose compared to 
57.1±11.9 relative CBF in single dose study). See FIG. 19A. 10 
Vehicle treatment (red) indicates that the animals underwent 
the same procedures but were given the diluent (solution the 
drug is suspended in) instead of drug. Arrows indicate cases 
when the drug (PEG-HCCs or vehicle) was administered 
intravenously. As illustrated in FIG. 19B, the relative CBF 15 
in the uninjured contralateral cortex was similar between 2 
dose PEG-HCCs and vehicle-treated rats (104.1±6.9 and 
93.5±5.9, respectively). As illustrated in FIG. 19C, the mean 
arterial blood pressure (MAP) was not significantly different 
between groups (p=0.507, RM ANOVA with Bonferroni 20 
post test). 
EXAMPLE 2D 
Materials and Methods 25 
30 
a solution of PEG in water, or a solution of PEG-HCCs in 
water. The final concentration of the PEG and PEG-HCCs in 
the treatment solution was 4 mg/L. Cells were incubated at 
37° C. with 5% CO2 for 5.5 h. The cells were then washed 
with ice cold PBS, then a solution of glycine (50 mM)/NaCl 
(100 mM), followed again by ice cold PBS in order to 
remove the carbon particles that are weakly attached to the 
membrane. Cells were fixed with 4% paraformaldehyde, 
then cell membranes were stained with Wheat Germ Agglu-
tinin 594 before being permeabilized with PBT (PBS con-
taining 0.1 % Triton X-100), blocked with 5% BSA in PBT, 
and immunostained with a primary antibody against PEG 
(Epitomics, PEG Rabbit Monoclonal Antibody, 
RabMAb® #: 2061-1) and an Alexa-633 conjugated sec-
ondary antibody, with DAPI used as a nuclear counterstain. 
Each set of images was taken with the same settings on a 
Zeiss LSM 510 META confocal microscope, and are shown 
at the same brightness/contrast levels. 
EXAMPLE 3 
Use of PEG-HCCs to Treat Oxidative Stress 
Associated with Non-Alcoholic Fatty Liver Disease 
This Example pertains to the use of PEG-HCCs to treat 
oxidative stress associated with Non-alcoholic fatty liver 
disease (NALFD). NALFD is an increasingly common 
disease that can range from simple steatosis to cirrhosis and 
bEnd.3 cells (ATCC) were grown in Dulbecco's modified 
Eagle's medium (4 mM L-glutamine adjusted to contain 1.5 
g/L sodium bicarbonate and 4.5 g/L glucose, 90%; fetal 
bovine serum, 10%) (Atlanta Biological) in an incubator set 30 liver failure. It is often comorbidity with obesity, diabetes, 
metabolic syndrome, and insulin resistance. Although its 
exact etiology is not clear, oxidative stress has been impli-
cated in the disease process both in animal models and 
human patients with NALFD. Antioxidants such as Vitamin 
to 37° C. with 5% CO2 . Aliquots of 60,000 cells in 0.5 mL 
were added directly onto sterile 25 mm round cover glasses 
inside 6 well plates. The cells were allowed to attach for 15 
min after which an additional 1.5 mL of media was added. 
Next, the cells were placed in an incubator and allowed to 
grow for 48 h. PEG-HCCs were added to each well to obtain 
the following concentrations: 0 mg/L, 0.1 mg/L, 1 mg/L, 10 
mg/L, 20 mg/L and 30 mg/L (triplicate). The cells were 
incubated for 1 h with the specific PEG-HCC concentrations 
after which 4,5-diaminofluorescein (DAF-2DA) at a final 40 
concentration of 5 mM was added to each well and incu-
bated for an additional 5 min. The cells were then washed 3x 
with PBS and fixed with 4% paraformaldehyde for 15 min. 
The cells were washed 3x with PBS and then the cover 
glasses were attached to glass slides and coverslipped. A 
Nikon eclipse 80i microscope set to FITC was used to 
capture ten 40x fields per slide. Five cells from each 40x 
field were analyzed using NIS Elements software. An auto 
detect region of interest (ROI) function was used to select 
the cells and calculate their mean intensity and area. The 
intensity/area/exposure was calculated. An ANOVA was 
performed using the means followed by post tests using the 
Bonferroni method. 
35 E have had limited success in NAFLD clinical trials which 
may be linked to the fact that each molecule of Vitamin E 
can only scavenge one radical before needing to be regen-
erated. Here, Applicants demonstrate that PEG-HCC treat-
ment can normalize hyperglycemia, reduce lipid peroxida-
tion markers, and improve liver enzymes in the leptin-
deficient (ob/ob) mouse model of NAFLD. 
NAFLD encompasses a spectrum of liver diseases, rang-
ing from simple steatosis and nonalcoholic steatohepatitis 
(NASH) to fibrosis and cirrhosis. With its prevalence esti-
45 mated to be over 30 million people in the United States, 
NAFLD is an increasingly common health concern. NAFLD 
is also closely associated with obesity, insulin resistance and 
the metabolic syndrome. A "two-hit" model has been pro-
posed to explain the development ofNAFLD. In this model, 
50 excess accumulation of lipids in the liver is a precondition 
("first hit"). Then a second insult to the liver such as 
inflammation and oxidative stress can induce progression 
from steatosis to more severe forms of NAFLD. Increased 
markers of oxidative stress have been found in both animal Confocal microscopy showed that the PEG-HCCs were 
taken up by the endothelial cells. See FIGS. 10-11. Staining 55 
against the PEG for the mock (FIG. lOB) and PEG (FIG. 
lOE) treated cells showed similar low intensity signals, 
indicating that uptake was dependent on the presence of 
carbon particles but not the PEG. The experiment was set as 
follows: bEnd.3 cells (-50,000/well, passage less than 30 60 
times) were grown on coverslips placed in 6-well plates with 
5 mL of complete media (high glucose Dulbecco's modified 
Eagle's medium (Gibco) formulated to contain 4 mM L-glu-
tamine, 3.7 g/L sodium bicarbonate, 4.5 g/L D-glucose, 1 
mM sodium pyruvate, 90%; fetal bovine serum, 10%; 1 x 65 
pen-strep). Cells were later treated with 5 mL of complete 
medium in a 1: 1 mixture with either water (Mock treatment), 
models and human patients with NAFLD. In addition, 
mitochondrial dysfunction and polymorphisms in the mito-
chondrial antioxidant superoxide dismutase 2 (SOD2) are 
associated with development and increased fibrosis in 
NAFLD. 
Clinical studies of the antioxidant Vitamin E in NAFLD, 
including two randomized controlled studies, have had 
mixed results. Several of these studies have demonstrated 
little to no benefit of vitamin E when compared to concomi-
tant weight loss. Other studies have found improved liver 
enzyme levels or better fibrosis scores. Antioxidants such as 
Vitamin E can only scavenge one radical per molecule 
before they must be regenerated by other antioxidants such 
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as Vitamin C, thus creating a process where the radicals get 
handed off instead of being completely captured or elimi-
nated. 
32 
was performed on samples to reduce interference from 
hemoglobin contamination. The supernatant was measured 
with a spectrophotometer. Malondialdehyde (MDA) levels 
were calculated from MDA standards. 
Statistics 
Leptin deficient obese (ob/ob) mice are a common model 
ofNAFLD. Although no NALFD model recapitulates all of 5 
the features of the human disease, ob/ob mice become obese, 
are hyperglycemic, and develop inflammation and severe 
steatosis. This Example examines the effectiveness of PEG-
HCCs or vitamin E in preventing liver damage in the ob/ob 
mouse model of fatty liver disease. 
EXAMPLE 3A 
Body weight, food intake, non-fasting glucose, insulin 
tolerance tests, and liver enzyme levels were analyzed by 
repeated measures analysis of variance (ANOVA) with 
Bonferroni post tests to identify specific groups that were 
10 different. Lipid peroxidation, lipid extraction data, and liver 
weights were measured with two way ANOVA and Bonfer-
Materials and Methods 
15 
Animal Procedures 
C57BL/6J wild type (WT, n=5/treatment) and B6.V-
Lep06/J (ob/ob, n=9-10/treatment) mice (Jackson Labs, Bar 
Harbor, Me.) were randomly assigned to one of three 
treatment groups: vehicle (PBS), PEG-HCCs, or Vitamin E 20 
chow (2.2 IU DL-alpha-tocopheryl acetate/g chow; Harlan, 
Teklad, Indianapolis, Ind.). Mice were housed in a 12 hour 
light and dark schedule. Body weight and non-fasting glu-
cose levels were measured weekly at the same time of day 
5-6 days post-treatment. Food intake was measured weekly 25 
for each cage. 
Drug Treatments 
Mice were treated weekly for six weeks with one of the 
following treatments: 100 µL vehicle (PBS) i.v.; 100 µL of 
200 mg/L PEG-HCCs in lxPBS i.v. (-0.02 mg HCC core/ 30 
mouse); 2.2 IU Vitamin E/g chow. Vitamin E treated WT and 
ob/ob mice averaged 8.2 and 11.6 IU Vitamin E/day, respec-
tively. 
Serum Collection 
For liver enzyme experiments, blood was collected from 35 
the saphenic vein using a microvette (Sarstedt, Niimbrecht, 
Germany) at baseline, 2 weeks, 4 weeks, and 6 weeks. Blood 
was collected with a microvette via a cardiac puncture at the 
end of the experiment for TBARS measurements. The blood 
was spun at 7500 rpm for 7 minutes. Serum was collected 40 
and stored at -80° C. until use. 
Liver Enzymes 
roni post tests. 
EXAMPLE 38 
Effects of PEG-HCCs on Weight, Food Intake, and 
Glucose Levels 
Body weight and food intake were monitored weekly in 
mice 5-6 days post-treatment. Both body weight and food 
intake were not significantly different within genotype using 
repeated measures ANOVA with a Bonferroni post-test. See 
FIGS. 20A-B. Wild-type (WT) mice weighed less and had 
lower food intake than ob/ob mice. However, antioxidant 
treatment did not affect these measures. On the other hand, 
non-fasting glucose levels for PEG-HCC-treated ob/ob mice 
were lower than the vehicle and Vitamin E treated ob/ob 
mice (RMANOVA; p<0.001, p<0.05, respectively), but not 
different from the WT mice. See FIG. 21. Both the vehicle 
and Vitamin E treated ob/ob mice had significantly higher 
glucose levels than their WT treatment counterparts 
(p<0.001, p<0.01, respectively). 
EXAMPLE 3C 
Effects of PEG-HCCs on Liver Enzyme Levels 
Aspartate aminotransferase (FIG. 22A), alanine amino-
transferase (FIG. 22B), and alkaline phosphatase (FIG. 22C) 
levels were measured from serum prior to treatment and 
again at 2, 4, and 6 weeks of treatment. PEG-HCC treatment 
lowered AST levels after 4 and 6 weeks of treatment. 
Vitamin E treatment lowered AST levels at 4 and 6 weeks of 
Alkaline phosphatase (ALP), alanine aminotransferase 
(ALT), and aspartate aminotransferase (AST) levels were 
measured from serum with colorimetric assays (Teco Diag-
nostics, Anaheim, Calif.). 
Tissue Collection 
45 treatment and briefly lowered ALT levels at 4 weeks. No 
significant changes were noted in alkaline phosphatase for 
Mice were euthanized with an overdose of anesthetic. 
Cardiac puncture was performed to collect blood. Liver was 
excised, weighed, and either flash frozen and stored at -80° 50 
C. or fixed in 4% paraformaldehyde overnight at 4° C. then 
dehydrated and embedded in paraffin. 
Lipid Extraction 
any time point or treatment. 
EXAMPLE 3D 
Effects of PEG-HCCs on Lipid Peroxidation 
Maldondialdehyde (MDA) levels were measured in 
serum as a marker of lipid peroxidation. Serum was taken 100 mg of liver tissue was homogenized on ice in buffer. 
300 µL of the homogenate was added to 600 µL of a 1: 1 
methanol chloroform mixture. The sample was vortex for 
one minute and then centrifuged. The methanol:chloroform 
layer was removed and dried in a new tube. 200 µL of 
chloroform was added to the dried sample and the samples 
were submitted to the Diabetes and Endocrinology core to 
be run on thin layer chromatography plates with lipid 
standards. 
55 after six weeks of treatment. As illustrated in FIG. 23, ob/ob 
mice had significantly higher MDA levels than WT 
(p<0.0001 ). Bonferroni post test showed that PEG-HCC and 
Vitamin E-treated ob/ob mice had lower MDA levels than 
vehicle treated ob/ob mice (p<0.01 and p<0.05, respec-
60 tively). See FIG. 23. 
Lipid Peroxidation 
Serum samples were tested for malondialdehyde levels 
with a TBARS kit (Cellbio Labs, San Diego, Calif.). Briefly, 65 
thiobarbituric acid was added to serum. Samples were 
incubated at 95° C. and then spun down. Butanol extraction 
EXAMPLE 3E 
Effects of PEG-HCCs on Lipids 
No significant changes were seen in the levels of hepatic 
cholesterol, free fatty acids, triglycerides, and cholesteryl 
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esters with weekly treatment with vehicle or PEG-HCCs for 
six weeks or daily administration of Vitamin E chow for six 
week. See FIG. 24. 
Discussion 
NAFLD is a complex disease pathology whose underly- 5 
ing causes are still not completely understood. Reactive 
oxygen species have been implicated in the pathogenesis of 
NAFLD as well as in its common comorbidities of diabetes 
and insulin resistance. Depletion of antioxidants and 
increased lipid peroxidation by-products have been reported 10 
in patients with NAFLD. It has been found that oxidative 
stress markers in humans such as TBARS and protein 
carbonylation were independently associated with NAFLD, 
regardless of gylcemic status. Mitochondrial dysfunction 15 
that impairs the mitochondrial respiratory chain can result in 
increased production of reactive oxygen species such as 
superoxide anion. Both mitochondrial dysfunction and 
reduced mitochondrial respiratory chain activity have been 
reported in human patients and mouse models of NAFLD. 20 
Genetic factors that can increase susceptibility to oxidative 
stress have also been associated with more advanced 
NAFLD. A polymorphism in the mitochondrial superoxide 
oxide dismutase (SOD2) gene that imparts reduced activity 
and targeting to the mitochondria has been linked to 25 
increased fibrosis in non-alcoholic steatohepatitis. Oxidative 
stress may play a role in triggering hepatic inflanmiation in 
obese NAFLD patients. 
Some groups have proposed that oxidative stress and 
mitochondrial dysfunction precede the appearance of insulin 30 
resistance. For instance, it has been reported that insulin 
resistance is a cellular antioxidant defense that could be 
induced by increased mitochondrial superoxide anion levels 
and reversed by mitochondrial superoxide dismutase mimet-
ics. In fact, even one of the common methods to produce a 35 
mouse model ofNAFLD, feeding mice a methionine choline 
deficient diet, has been reported to induce mitochondrial 
respiratory chain dysfunction and increased oxidative stress. 
In this Example, Applicants have reported that treatment 
of ob/ob mice with the nano-antioxidant PEG-HCCs once 40 
weekly for 6 weeks eliminated hyperglycemia, reduced 
aspartate aminotransferase levels, and lowered lipid peroxi-
dation levels. Daily vitamin E treatment was also able to 
reduce aspartate aminotransferase levels and lower lipid 
peroxidation markers, but not restore normal glucose levels. 45 
Similar improvements have been seen in some of the clinical 
trials with Vitamin E and NAFLD. None of the treatments 
caused any significant change in body weight, liver weight, 
or food intake in WT or ob/ob mice. The ob/ob mice had 
significantly higher body weight, liver weight, and food 50 
consumption than their WT counterparts as expected in this 
mouse model. 
NAFLD is a complex disease involving many different 
pathways and pathogenic processes. Therefore, therapeutic 
approaches to NAFLD can also be multi-pronged to address 55 
different aspects of the disease processes. For instance, 
PEG-HCCs can also be loaded with payload drugs that can 
target other sources of NAFLD pathology such as steatosis 
or inflanmiation. 
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cells (b.End3). Applicants also show that SWNTs and PEG-
HCCs are able to protect b.End3 cells from oxidative stress. 
EXAMPLE 4A 
Materials and Methods 
Preparation of pluronic-wrapped SWNTs (pl/SWNTs) 
and PEG-HCCs 
SWNTs (lot# HPR 187.4) were purchased from HiPco 
Laboratory at Rice University. The SWNTs were purified 
following a reported protocol. Chem. Mat. 2009 (21 ):3917-
3923. The purified SWNTs (0.07 g) and Pluronic F 108NF 
Prill Poloxamer 338 (donated by the BASF Corporation, 
2.25 g) in NANOPure water (Barnstead system, 18 MQ 
resistivity, 225 mL) were homogenized for 1 h by using a 
homogenizer shaft driven by a Dremel Multipro model 395 
motor and model 225 flexible shaft. The mixture was then 
sonicated by using a cup-horn sonicator (Cole Parmer Ultra-
sonic Processor Model CP 750) for 10 min at 78% ampli-
tude. The mixture was then ultracentrifuged for 6 hat 26,000 
rpm. The pl/SWNTs in solution were decanted, and the solid 
material was discarded according to established approved 
protocols. The concentration of the resultant pl/SWNTs, 
determined by Beer's law analysis using an empirically 
derived extinction coefficient of 0.0430 L/mg at "-max =763 
nm, was 10 mg/L. The solution was concentrated using a 
rotary evaporator and sterile filtered using a 0.45 µm pore 
size membrane, producing a final solution with a pl/SWNTs 
concentration of 12 mg/L. 
The PEG-HCCs were prepared as recently reported. ACS 
Nano. 2010 (4):4621-4636. The PEG-HCCs were sterile 
filtered using a 0.22 µm pore size membrane. 
Cell Culture 
Murine brain endothelioma (bEnd.3, CRL 2299, ATCC, 
Manassas, Va.) were cultured in Dulbecco's Modified Eagle 
Medium: Nutrient Mixture F-12 (50:50) with 4 mM L-glu-
tamine media, supplemented with 10% fetal bovine serum 
(both from HyClone) and 1 % Pen Strep ( + 10,000 u/mL 
penicillin/+10,000 µg/mL streptomycin, from GIBCO). Dur-
ing the second week, between the 4th and 6th passage, cell 
experiments were performed. 
Clonogenic Survival Assay 
Following a published protocol (Nat Protoc 2006(1): 
2315-2319), this assay was carried out three times for each 
concentration of the PEG-HCCs and pl/SWNTs. For each 
nanomaterial treatment, 30,000 cells/mL were plated in 5 
mL of full media. After 24 h, the media was removed, and 
the cells were washed with 1 x phosphate buffered saline 
(PBS). The cells were treated with the desired concentra-
tions of nanomaterials in 5 mL full media and incubated for 
24 h. Cells were detached using 1 mL of 0.25% trypsin and 
0.1 % ethylenediaminetetraacetic acid for 5 min and then 
suspended with an additional 4 mL full media. The number 
of cells in the 5 mL suspension was determined using a 
hemocytometer and 2000 cells were plated to assay colony 
formation. Colonies were defined to consist of at least 50 
cells. When colonies were sufficiently large on control plates 
EXAMPLE 4 
Effects of PEG-HCCs and SWNTs on Brain 
Endothelial Cells 
60 (generally after 7-14 d), the media was aspirated and the 
plates gently washed by submersion in water. Colonies were 
stained using 2 mL of 0.25% crystal violet (Sigma-Aldrich, 
catalog C0775) in methanol for 3 min. The plates were 
gently washed with water to remove excess stain, and 
In this Example, Applicants show that SWNTs and PEG-
HCCs are biocompatible with cultured brain endothelial 
65 air-dried at room temperature. Stained colonies were 
counted. Values were normalized to the O mg/L nanomaterial 
control. 
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Trypan Blue Staining 
The following protocol was carried out three times for 
each concentration of the PEG-HCCs and pl/SWNTs. For 
each nanomaterial treatment, 150,000 cells were plated in 
full media in four 6-cm plates. After incubation for 24 h, the 5 
media was removed, and the cells were washed with 1 xPBS. 
The cells were treated with the desired concentrations of 
nanomaterials in 5 mL full media. For the pl/SWNTs, the 
samples were prepared such that the concentration of 
pluronic was kept constant at 1 % by weight. The treated 10 
cells were incubated for 6 h or 24 h. Cells were detached 
using 1 mL of 0.25% trypsin and 0.1 % ethylenediaminetet-
raacetic acid for 5 min and then suspended with an addi-
tional 4 mL of serum free media. Cells were pelleted twice 15 
at 1,000 rpm for 5 min and washed in lxPBS. Cells were 
then resuspended in 1 mL 1 xPBS and mixed with 1 mL of 
0.4% trypan blue solution (Invitrogen, Carlsbad, Calif.). 
After 5 min, an aliquot of the cells was removed and blue 
(dead cells) and non-stained cells were counted in 4 quad- 20 
rants of a hemocytometer. After 15 min, another aliquot was 
removed and the count was repeated. The values presented 
are the average of the counts, and the values were normal-
ized to the O mg/L nanomaterial control. The exposure of 
cells to trypan blue for a period longer than 30 min was 25 
avoided. At extended times, an increase in the dead cell 
population due to the trypan toxicity was observed. 
Cyctochrome C Assay for Antioxidant Strength 
Superoxide scavenging efficiency was determined using a 
method described previously. J. Neurosci. Methods. 2000 30 
(97):139-144. Briefly, three reaction solutions were pre-
pared, A-C. Solution A contained catalase (320 µl; 6000 
U/mL in PBS; Sigma-Aldrich), hypoxanthine (320 µl; 10 
mM solution in 30 mM NaOH; Sigma-Aldrich), cytochrome 
c (755 µl; 1.95 mM solution in PBS; Sigma-Aldrich), and 35 
14.6 mL of PBS. Solution B consisted of xanthine oxidase 
(57 µL; 167.5 mU/mL in PBS; Sigma-Aldrich) and PBS 
(743 µL). Additional B solutions were prepared with the test 
antioxidant compounds, pl/SWNTs and PEG-HCCs, replac-
ing the PBS in volumes ranging from 1-7 43 µL. All solution 40 
B preparations were 800 µl, enough solution to run four 
replicates of each antioxidant concentration. Solution C 
included Xanthine oxidase (57 µL; 167.5 mU/mL in PBS), 
superoxide dismutase (90 µL; 10200 U/mL in PBS; Sigma-
Aldrich), and PBS (653 µL) to allow determination of 45 
non-superoxide-dependent reduction of cytochrome c (total 
volume 800 µL). 
The assay was performed in a 96-well plate with a final 
reaction volume of325 µL per well. Each plate contained the 
following conditions, using four wells for each condition: 50 
(1) a water blank (325 µL per well), (2) solution B without 
any nanomaterials (the control reaction; 162.5 LI per well), 
(3) solution B with the nanomaterials (162.5 µL per well), 
and (4) solution C, containing SOD (162.5 µL per well). 
After all of the above solutions had been added to the plate, 55 
162.5 µL of solution A was rapidly added to each well except 
for the water blanks. Two min after the addition of solution 
A, a BIO-TEK Powerwave XS spectrophotometer (Win-
ooski, Vt.) supported by SOFTmax Pro software (Molecular 
Devices, Sunnyvale, Calif.) was used to read the plate at 550 60 
nm on a basic kinetic protocol to measure absorbance every 
45 s, for a total reaction time of 8 min. The reaction rate 
(OD/min) was determined and then plotted against the log of 
the concentration of the test compound. IC50 was determined 
using a nonlinear regression analysis (GraphPad Prism soft- 65 
ware version 5.0, La Jolla, Calif.). For each nanomaterial, 
this entire assay was performed at least three separate times. 
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b.End3 Cell Staining for Von Willebrand Factor 
bEnd.3 cells (200,000/well, passaged fewer than 10 
times) were plated onto 25 mm poly-D-Lysine-coated glass 
disks placed within 6-well plates. To each well was added 2 
mL of complete growth medium (Dulbecco's modified 
Eagle's medium with 4 mM L-glutamine adjusted to contain 
1.5 g/L sodium bicarbonate and 4.5 g/L glucose, 90%; fetal 
bovine serum, 10%, ATCC, Manassas, Va.). Cells were 
incubated at 37° C. with 5% CO2 for 24 h. After incubation, 
the cells were fixed in 100% methanol at -20° C. for 5 min. 
The methanol was removed and the cells were dried at room 
temp in a biological hood. To the fixed cells, 2 mL of 0.1 % 
Triton X-100 in PBS was added. After 30 min, the cells were 
washed 3x with PBS. The cells were then incubated for 30 
min in 2 mL of 3% normal goat serum and then washed 3x 
with PBS. Cells were then incubated overnight at 4° C. in the 
presence of a 1 :400 dilution of the primary antibody (Poly-
clonal Rabbit Anti-Human Von Willebrand Factor antibody, 
DAKO, Glostrup, Denmark) in PBS. Next, the cells were 
washed 3x in PBS. The cells were then incubated with a 
1:1000 dilution of the secondary antibody (Alexa Fluor goat 
anti-rabbit 594, Invitrogen, Carlsbad, Calif.) for 4 hat room 
temp in the dark. Cells were then washed 3x with PBS. The 
25 mm disks were then removed from the wells and attached 
to glass slides using an adhesive (clear nail polish). Cover-
slips were then applied using Vectashield Hard Set Mount-
ing Medium with DAPI (Vector Labs, Burlingame, Calif.) 
and allowed to harden at 4 ° C. in the dark. The slides were 
then analyzed using a Nikon Eclipse 80i epi-fluorescense 
microscope. Von Willebrand Factor was detected with Texas 
Red; DAPI is blue. 
Antimycin A/DHE Assay for Intracellular Antioxidant 
Strength 
Cells were treated as previously described (Biochem. J. 
2009(418):29-37), with slight modification to accommodate 
antioxidant treatment and cell type. Briefly, bEnd.3 cells 
were grown in 6-well culture plates for 72 h. Culture media 
was reduced to 1 mL. Cells were treated with lxPBS (5 µl) 
or 2 mM antimycin A (5 µl Sigma-Aldrich, St. Louis, Mo.), 
which induces intracellular ROS. The cells were then incu-
bated for 10 min at 37° C. and 5% CO2 . Antioxidant 
treatments were then given as follows: PEGylated SOD ( 4 
U, Sigma-Aldrich), N-tert-Butyl-alpha-phenylnitrone (PBN; 
2 µl of 300 mM; Acros Organics, Geel, Belgium), PEG-
HCCs (1, 10, 20, 40 µL of 100 mg/L), and pl/SWNT (10, 40 
µL of 12 mg/L). Controls run to assess baseline antioxidant 
nanomaterial fluorescence used the highest volume listed 
above for each nanomaterial. 
Dihyroethidium (DHE; 1 µL of 5 mM; Fluka Chemie 
GmbH, Buchs, Switzerland) was added 5 min later and the 
cells were incubated at 37° C. and 5% CO2 for 25 min. Cells 
were washed twice with lxPBS, removed from the wells 
with 0.5 mL trypsin, suspended in 2 mL PBS with 2% fetal 
calf serum in fluorescent-activated cell sorting tubes, and 
washed twice. SytoxRED (1 µl Invitrogen, Carlsbad, Calif.) 
was added to each tube. 15 min later, and cells were run on 
a flow cytometer (BD FACSCanto II, San Jose, Calif.). For 
each sample, 10,000 cells were analyzed, and the mean 
fluorescent intensity was measured with assistance from the 
cytometry and cell sorting core ( 488 nm excitation laser for 
DHE detection and 637 nm excitation laser for SytoxRED 
detection). DHE reacts with ROS to form 2-hydroxy-
ethidium, which possesses red fluorescence when excited 
near 480 nm. Thus, the increase in red fluorescence is 
proportional to the ROS in the sample. The mean fluorescent 
intensity for each experiment repetition was normalized to 
US 9,572,834 B2 
37 
control cells from that individual experiment to avoid error 
due to daily fluctuations in the lasers. 
Two additional control experiments were performed to 
test whether prolonged pretreatment exposure to known 
antioxidants was able to reduce superoxide levels from 5 
antimycinA treatment. In these cases, an identical procedure 
38 
disrupted by oxidation. The surface of the HCCs may also 
bear a number of functional groups, including ketones, 
alcohols, epoxides and carboxylic acids, such that, stoichio-
metrically, for every four carbons there may be one oxygen. 
Furthermore, as illustrated in FIG. lD, solubilizing PEG 
groups may be covalently attached to the PEG-HCCs via a 
N,N'-dicyclohexylcarbodiimide-mediated coupling to the 
carboxylic acids. One way in which these differences are 
reflected is in the concentrations that can be achieved in 
aqueous solutions. These concentrations are measured for 
the carbon core of each nanomaterial using UV analysis. For 
instance, the PEG-HCCs can be soluble in water at 1000 
mg/L, while the concentrations achieved for dispersed 
pl/SWNTs are generally around 10 mg/L for the SWNTs 
to that described above was followed, except that after the 
cells had grown in the 6-well plates for 58 h, they were 
treated with either 40 U PEGylated SOD or 20 µL 300 mM 
PBN. Fourteen h later, at the 72 h time point, the cells were 10 
treated with lxPBS (5 µL) or 2 mM antimycinA(5 µL). The 
cells were then incubated for 10 min at 37° C. and 5% CO2 . 
The cells were then treated again with either 40 U/well 
PEGylated SOD or 20 µL 300 mM PBN. DHE staining and 
analysis was identical to that described above. 15 used in this work. 
Protection ofb.End3 Cells from Oxidative Stress-Induced 
Death 
bEnd.3 cells (-200,000/well, passaged less than 10 times) 
were plated in 6-well plates. To each well was added 2 mL 
of complete growth medium (Dulbecco's modified Eagle's 20 
medium with 4 mM L-glutamine adjusted to contain 1.5 g/1 
sodium bicarbonate and 4.5 g/1 glucose, 90%; fetal bovine 
serum, 10%, ATCC, Manassas, Va.). Cells were incubated at 
37° C. with 5% CO2 for 72 h. Media was removed and 
replaced with 1 mL fresh media. Cells were then treated with 25 
15 µI/well 3 mM antimycin A or lxPBS. This dose of 
antimycin A was selected empirically to provide a midrange 
toxicity towards the bEnd.3 cells. Cells were incubated at 
37° C. with 5% CO2 for 10 min then one of the following 
was added: 40 µL of 100 mg/L PEG-HCCs, 40 µL of 12 30 
mg/L pl/SWNTs, 40 U PEGylated SOD, or 20 µL of300 mM 
PBN. Cells were then incubated at 37° C. with 5% CO2 for 
24 h. Cells were washed twice with 1 xPBS, removed from 
wells with 0.5 mL trypsin, suspended in 2 mL PBS with 2% 
fetal calf serum, and washed twice. Cells were resuspended 35 
in 0.5 mL lxPBS and counted on a Vi-Cell XR Analyzer 
(Becknian Coulter, Brea, Calif.). Viable cells/mL was 
recorded and the percent relative to control was calculated 
from the PBS-treated control cells. 
Statistical Methods 
Assays for intracellular antioxidant strength and oxidative 
stress-induced death were analyzed with one-way analysis 
40 
of variance (ANOVA) followed by a Bonferroni post test to 
compare all groups. Assays for toxicity were analyzed by 
comparing each treatment to the control treatment for that 45 
experiment using a two-tail T-test assuming equal variances. 
A p-value <0.05 was considered significant. 
EXAMPLE 48 
EXAMPLE 4C 
Inhibition of Cytochrome C Oxidation by 
PEG-HCCs and pl/SWNTs 
The ability of the pl/SWNTs and PEG-HCCs to quench 
ROS was evaluated by exposing them to superoxide anion 
generated by the metabolism of hypoxanthine by xanthine 
oxidase. Since the carbon cores of the pl/SWNTs and 
PEG-HCCs can play a role in their antioxidant properties, 
their ability to inhibit the oxidation of cytochrome c was 
calculated on this basis. Both the PEG-HCCs and the 
pl/SWNTs were effective antioxidants and were able to 
achieve inhibition equivalent to half that of the positive 
control (IC50), which was a large excess of SOD. See FIG. 
25. The IC50 values were 200 mg/L for the PEG-HCCs and 
0.61 mg/L for the pl/SWNTs. 
EXAMPLE 4D 
Evaluation of the Toxicity of PEG-HCCs and 
pl/SWNTs 
The potential cytotoxicity of the pl/SWNTs and PEG-
HCCs was evaluated using b.End3 cells. See FIG. 26. It was 
first confirmed that this cell line is an endothelial cell line, 
based on the expression of Von Willebrand Factor. See FIG. 
26A. 
To evaluate the effects of PEG-HCCs and pl/SWNTs on 
b.End3 cells, Applicants utilized a trypan blue assay. See 
FIG. 268. Trypan blue is a membrane-impermeant dye so it 
only stains dead or dying cells with damaged membranes. 
The b.End3 cells were incubated in the presence of various 
Characterization of PEG-HCCs and pl/SWNTs 
FIG. lD illustrates a scheme for preparing PEG-HCCs 
and pluronic wrapped SWNTs (pl/SWNTs). PEG-HCCs are 
soluble in water and other biologically relevant solutions, 
such as PBS or cell culture media. On the other hand, the 
SWNTs are insoluble in these solutions. In order to use 
them, the SWNTs were wrapped with pluronic (pl/SWNTs ). 
Pluronic (BASF Corporation) is a triblock copolymer of 
poly( ethylene glycol)/poly(propylene glycol)/poly( ethylene 
glycol). The pl/SWNTs and PEG-HCCs vary in size, shape 
and surface functionality. SWNTs are generally long (500 
nm-5 µm) and tubular. The poly(propylene glycol) block of 
the pluronic wraps around the SWNTs' nearly pristine 
carbon surfaces, thereby imparting aqueous solubility. 
50 concentrations of the PEG-HCCs (0-200 mg/L) and 
pl/SWNTs (0-10 mg/L) for 6 hand then stained with trypan 
blue for live/dead cell counting. As shown in FIG. 26B, no 
toxicity was observed at this time point for any of the 
concentrations of either material. However, when the incu-
On the other hand, HCCs are generally shorter ( e.g., 
<40-nm-long). In addition, the HCC side walls may be 
55 bation time was extended to 24 h, a clear difference between 
the materials was observed, as the PEG-HCCs were still 
non-toxic while the pl/SWNTs were cytotoxic. Applicants 
further investigated this difference in toxicity by performing 
a clonogenic survival assay. See FIG. 26C. For this assay, 
60 b.End3 cells were incubated in the presence of various 
concentrations of the PEG-HCCs (0-200 mg/L), pl/SWNTs 
(0-10 mg/L) or 1 % pluronic only for 24 h. Then, for each 
treatment, an equal number of cells were transferred to a 
new culture dish and allowed to grow until the control dish 
65 showed a sufficient number of colonies for counting. This 
generally occurred after 7-14 d, at which time all of the 
plates were stained and the number of colonies was deter-
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mined for each treatment and compared to the control. The 
PEG-HCCs were once again non-toxic at all of the concen-
trations tested. On the other hand, Applicants found that 1 % 
pluronic alone was highly toxic under these conditions, 
resulting in just 7% colony formation relative to control. 5 
Due to the magnitude of the toxicity associated with 1 % 
pluronic, it cannot be determined in these cellular assays if 
the SWNTs contributed to the toxicity seen for the 
pl/SWNTs. 
cell survival equal to that of the control treatment, while 
treatment with pl/SWNTs, PEGylated SOD or PBN resulted 
in cell survival at 85% of this value. 
Since PEG-SODs and PEG-HCCs had higher baseline 
survival/proliferation, Applicants calculated the percent 
recovery of each antioxidant from the antimycin A-treated 
cells to each antioxidants' initial baseline. By this calcula-
tion, the levels of protection were 66% for PEG-HCCs, 46% 
for pl/SWNT, 48% for PBN and 23% for SOD. See FIGS. 
EXAMPLE 4E 
Antioxidant Activities of PEG-HCCs and 
pl/SWNTs in Living Cells 
Having established that the PEG-HCCs were not toxic to 
b.End3 cells, their ability to quench intracellular ROS was 
evaluated. Since the pl/SWNTs did not cause cell death in 
the first 6 h, they were included in the assay for comparison. 
The b.End3 cells were treated with antimycin A, an electron 
transport chain blocker known to increase mitochondrial 
superoxide production. After 15 min, the cells were treated 
with either PEG-HCCs, pl/SWNTs, PEGylated SOD, PBN 
or PBS. The cells were then stained with DHE and the 
intensity of the resulting fluorescence was measured to 
monitor the production of the ROS superoxide. All samples 
were normalized relative to the fluorescence measured for 
the control cells without DHE or antimycin A treatment. 
Controls were performed that demonstrated that the nano-
materials neither had appreciable fluorescence on their own 
nor interfered with the DHE fluorescence at the concentra-
tions employed. See FIG. 27. Both the PEG-HCCs and 
pl/SWNTs reduced, in a dose-dependent manner, the ROS 
levels in b.End3 cells that were stressed with antimycin A. 
See FIGS. 28-29. In fact, both the PEG-HCCs and 
pl/SWNTs reduced ROS levels in these stressed cells to the 
level observed in b.End3 cells not treated with antimycin A. 
For comparison, two known antioxidants, PEGylated SOD 
and PBN, were used in concentrations similar to the nano-
materials and were administered using the same protocol 
that was used for the nanomaterials. Under these conditions, 
PEGylated SOD and PBN showed minimal efficacy, possi-
bly because they were not internalized by the cells due to the 
short duration of exposure. When larger doses of PEGylated 
SOD and PBN were used and the treatment was given both 
14 h prior and 15 min after exposure to antimycin A, then a 
decrease in ROS was achieved that was equivalent to that 
observed for treatment with the nanomaterials after admin-
istration of antimycin A. 
10 30-31. 
Discussion 
In this Example, Applicants demonstrated that both PEG-
HCCs and pl/SWNTs are able to eliminate ROS. The ROS 
were generated by the metabolism of hypoxanthine by 
15 xanthine oxidase. The antioxidant ability of the nanomate-
rials was determined by monitoring the SOD-inhibitable 
reduction of ferricytochrome c. 
The cytotoxicity of the nanomaterials towards b.End3 
cells was also studied. PEG-HCCs showed no toxicity, even 
20 when used at a concentration 50x higher than that which 
showed the maximal reduction in intracellular ROS. On the 
other hand, the results indicated that, over a longer period of 
time, the pl/SWNTs were potentially toxic at 10 mg/L. 
Applicants further investigated this difference in toxicity by 
25 performing a clonogenic survival assay. The PEG-HCCs 
were once again non-toxic at all of the concentrations tested. 
On the other hand, Applicants found that 1 % pluronic alone 
was highly toxic under these conditions, resulting in just 7% 
colony formation relative to control. Due to the magnitude 
30 of the toxicity associated with 1 % pluronic, it cannot be 
determined in these cellular assays if the SWNTs contrib-
uted to the toxicity seen for the pl/SWNTs. The possibility 
still exists for applying pl/SWNTs in vivo as antioxidants, as 
they have been previously monitored in vivo and they 
35 showed no toxicity, as the pluronic is rapidly diluted and 
even displaced from the SWNTs. 
Since both nanomaterials could be used safely over a 
short period of time, their ability to eliminate intracellular 
ROS was tested using a rapid assay in which b.End3 cells 
40 were stressed for 15 min with antimycin A to generate 
superoxide, treated for 5 min with the nanomaterials and 
then DHE to measure the levels of ROS. Since superoxide 
does not readily cross cell membranes, this assay tested the 
ability of these antioxidants to protect from primarily an 
45 intracellular insult. This method was selected after evaluat-
ing a variety of assays for potential interference from the 
carbon nanomaterials. Both the PEG-HCCs and the 
pl/SWNTs were able to quench the antimycin A-induced 
Since these studies indicated that both PEG-HCCs and 50 
ROS in a dose-dependent manner. Again, the pl/SWNTs 
were more potent, as a dose of just 0.48 mg/L of the 
pl/SWNTs lowered the amount of ROS to the background 
level, while a dose of 2-4 mg/L was required for the 
PEG-HCCs to achieve the same effect. Interestingly, when 
PEGylated SOD or PBN was administered at a similar 
pl/SWNTs could reduce DHE fluorescence to baseline levels 
in this model of oxidative stress, the two antioxidant nano-
materials were also evaluated under more severe oxidative 
stress models. In this experiment, the b.End3 cells were 
treated with a larger dose of antimycin A empirically deter-
mined to create approximately 30% reduction in cell sur-
vival. See FIGS. 30-32. 
The test antioxidants were incubated with the cells for 24 
55 weight equivalent to the PEG-HCCs, no effect was 
observed. This could be the result of more rapid internal-
ization of the nanomaterials compared to the PEGylated 
SOD and PBN. The rapidity of the nanomaterials' efficacy 
is promising for in vivo applications. 
Since both PEG-HCCs and pl/SWNTs could fully elimi-
nate the ROS from a mild oxidative stress, their effect on a 
cell-killing stressor was evaluated. Cells were exposed to a 
higher concentration of antimycin A empirically determined 
to kill approximately 30% of the cells and then cells were 
h following treatment with antimycin A and cell survival 
was determined. Under the control conditions, in which the 60 
cells were not treated with antimycin A, PEGylated SOD 
increased cell survival/proliferation by 27%. A similar trend 
was seen with the PEG-HCCs, while PBN and pl/SWNTs 
did not have significant effects. However, when the cells 
were stressed with antimycin A and then treated with the test 
antioxidants, the PEG-HCCs were the more effective agents 
for protecting the cells. The PEG-HCC treatment resulted in 
65 treated with pl/SWNTs, PEG-HCCs, PEGylated SOD or 
PBN. A set of controls was also run in which the cells were 
only treated with PEG-HCCs, pl/SWNTs, PEGylated SOD 
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or PBN. Under the control conditions, in which the cells 
were not treated with antimycin A, both the PEG-HCCs and 
the SOD increased cell survival while PBN and pl/SWNTs 
did not have any effect. This is possibly due to the PEG-
HCCs and the SOD increasing the level of antioxidants in 5 
the culture media. However, when the cells were stressed 
with antimycin A and then treated with the test antioxidants, 
the PEG-HCCs were the most effective at protecting the 
42 
been seen in acute conditions such as head trauma as well as 
the dependence of most of these antioxidants on subsequent 
radical scavenging. 
Based on the above-mentioned observations, Applicants 
envision the use of the carbon nanomaterials of the present 
disclosure to effectively reduce ROS formation in AD. 
Applicants propose that the use of the carbon nanomaterials 
of the present disclosure could provide a novel approach to 
treat Alzheimer's Disease. Applicants' data presented herein 
cells, in both an absolute and relative sense. 
10 provide support for this approach. 
EXAMPLE 5 
Use of PEG-HCCs to Treat Oxidative Stress 
Associated with Alzheimer's Disease 
15 
Alzheimer's disease (AD) is a progressive neurodegen-
erative disease characterized by the neuropathological accu-
mulation of amyloid beta (AR) deposition as well as neu-
rofibrillary tangles. Current therapies for AD primarily 20 
target the symptoms, while treatments to halt or reverse the 
course of the disease remain experimental. Although the 
potential neurotoxic effect of AR has been long established, 
its specific role in the cascade of events leading to memory 
impairments is unknown. Several reports propose a link 25 
between AR and oxidative stress to explain the downstream 
cognitive deficits observed in AD. Specifically, it has been 
shown that AR promotes oxidation in several model systems 
and conversely, pro-oxidants increase the production of Af3. 
One of the major characteristics of AD is the deposition 30 
of amyloid plaques. Transgenic animals such as the Tg2576 
model that over-express a mutated form of APP (Swedish 
mutation), exhibit increased AR levels at an early age (i.e., 
6 months) followed by the development of neuritic plaques 
and cognitive defects by 8-9 months of age. AB peptides 35 
exhibit oxidant properties and can compromise mitochon-
drial function. For example, soluble AB species have been 
linked to an increase in hydrogen peroxide and a decrease in 
cytochrome C oxidase activity in the Tg2576 mouse model. 
Additionally, AR has been shown to enter the mitochondria 40 
and cause an amplification cascade that leads to inactivation 
EXAMPLE SA 
PEG-HCCs Reduce ROS Formation in T22576 
Mice 
FIG. 33 shows preliminary data indicating that PEG-
HCCs can reduce ROS formation in Tg2576 mice upon 
intraperitoneal (IP) administration. In this Example, mice 
were injected intraperitoneally with vehicle samples (Con-
trol) or PEG-HCCs. The dose of PEG-HCCs was 200 RI of 
150 mg/I solution. Mice were injected at 24 and 48 hours 
prior to euthanasia (DHE was administered at the 24 hour 
time point). Mice were euthanized and the DHE/DAPI ratio 
in the hippocampus was assessed. Applicants observed a 
significant increase in DHE staining in the Tg2576 mice, 
reflective of increased ROS formation. However, in the 
Tg2576 mice treated with PEG-HCCs, Applicants observed 
a normalization of the DHE staining, indicating that ROS 
formation was reduced back to wildtype levels. Overall, 
these results demonstrate that treatment with the PEG-HCCs 
can reduce ROS formation in the 14-15 sections Tg2576 
mouse brains. 
Based on the above findings, Applicants envision that the 
carbon nanomaterials of the present disclosure can signifi-
cantly reduce ROS formation in the Tg2576 mouse model of 
AD, thereby leading to significant improvements (behav-
ioral, biochemical and physiological) similar to what Appli-
cants observed in the Tg2576/SOD-2 mice. Additionally, 
based on the above results, Applicants expect behavioral, 
axonal transport and cerebral blood flow improvements, as 
well as reduced plaque formation with the functionalized 
PEG-HCCs and HCCs. 
of SOD-2 and generation of additional free radicals. Also 
consistent with a pathogenic interaction between AS and 
mitochondria, SOD-2 knockout mice exhibit an increased 
plaque burden. Furthermore, SOD-2 immunohistochemistry 
from post-mortem human AD brain samples demonstrates a 
global increase in SOD-2 as a compensatory mechanism to 
oxidative stress associated with AD. 
Without further elaboration, it is believed that one skilled 
45 in the art can, using the description herein, utilize the present 
disclosure to its fullest extent. The embodiments described 
Applicants' prior work has established that the mitochon-
drial enzyme, superoxide dismutase 2 (SOD-2), is involved 50 
in the pathogenesis of AD in a mouse model. In particular, 
Applicants previously tested if over-expression of SOD-2 
could prevent AD-related pathology and memory impair-
ments in a mouse model of AD (Tg2576) through subse-
quent reduction in reactive oxygen species (ROS). PNAS, 55 
2009. 106(32): 13576-81. Based on such findings, Applicants 
envision that the impact of ROS may be a key event in the 
initiation of AD-related pathology and memory deficits. 
However, antioxidant trials have produced conflicting 
results, perhaps due to lack of potency, as seen in acute 60 
injury studies and the dependence on intrinsic radical scav-
enging due to subsequent radical transfer. For example, 
superoxide dismutase, while reducing superoxide radical 
levels, generates hydrogen peroxide which then depends on 
additional enzymatic activity to reduce overall oxygen radi- 65 
cal activity. Potential reasons for these conflicting results 
include the lack of potency of available antioxidants, as has 
herein are to be construed as illustrative and not as con-
straining the remainder of the disclosure in any way what-
soever. While the embodiments have been shown and 
described, many variations and modifications thereof can be 
made by one skilled in the art without departing from the 
spirit and teachings of the invention. Accordingly, the scope 
of protection is not limited by the description set out above, 
but is only limited by the claims, including all equivalents of 
the subject matter of the claims. The disclosures of all 
patents, patent applications and publications cited herein are 
hereby incorporated herein by reference, to the extent that 
they provide procedural or other details consistent with and 
supplementary to those set forth herein. 
What is claimed is: 
1. A method of treating oxidative stress m a subject, 
wherein the method comprises: 
administering a therapeutic composition to reduce the 
levels of reactive oxygen species in the subject, 
wherein the therapeutic composition includes a poly-
ethylene glycol functionalized hydrophilic carbon clus-
ter (PEG-HCC), conjugated with: (i) a plurality of 
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aromatic domains and (ii) an adamantane derivative 
covalently bound to the terminus of the polyethylene 
glycol functionality of the PEG-HCCs. 
2. The method of claim 1, wherein the anti-oxidant 
activity of the carbon nanomaterial corresponds to ORAC 
values between about 200 to about 15 000 
3. The method of claim 1, wherein ;he l~vels of reactive 
oxygen species in the subject are reduced by about 5% to 
about 75%. 
4. The method of claim 1, wherein the therapeutic com-
position reduces the levels of one or more of the reactive 
oxygen species: nitric oxides, superoxides, hydroperoxyls, 
hydrogen peroxide, oxygen radicals, hydroxyl radicals, 
organic hydroperoxides, alkoxy radicals, peroxy radicals, 
hypochlorous acids, peroxynitrites, and combinations 
thereof. 
5. The method of claim 1, wherein the subject is a human 
being. 
6. The method of claim 1, wherein the administering of 
the therapeutic composition comprises intravenous admin-
istration. 
7. The method of claim 1, wherein the administering of 
the therapeutic composition is for treating a disease or 
ischemic condition selected from the group consisting of 
traumatic brain injury, ischemia, anoxic encephalopathy 
hypoxic or ischemic encephalopathy, cerebrovascular dys~ 
function, hemorrhagic shock, hypoxia, hypotension, 
Alzheimer's disease, Parkinson's disease multiple sclerosis 
amyotrophic lateral sclerosis, liver dis~ase, non-alcoholi~ 
fatty liver disease, diabetes, stroke, inflammation, spinal 
cord injury, central nervous system injury or neuropathy, 
organ transplantation, and combinations thereof. 
8. The method of claim 7, wherein the disease or ischemic 
condition is associated with traumatic brain injury. 
9. The method of claim 1, wherein the oxidative stress is 
associated with cerebrovascular dysfunction following trau-
matic brain injury. 
10. The method of claim 1, wherein administering of the 
therapeutic composition is for treating non-alcoholic fatty 
liver disease. 
11. The method of claim 1, wherein the hydrophilic 
c~bon cluster is selected from the group consisting of 
smgle-walled nanotubes, double-walled nanotubes, triple-
walled nanotubes, multi-walled nanotubes, ultra-short nano-
tubes, graphene, graphene nanoribbons, graphite, graphite 
oxide nanoribbons, carbon black, oxidized carbon black and 
combinations thereof. ' 
12. The method of claim 1, wherein the hydrophilic 
carbon cluster is functionalized with a plurality of solubi-
lizing groups. 
13. The method of claim 12, wherein the solubilizing 
groups are selected from the group consisting of poly 
(ethylene glycol), poly(propylene glycol), poly(vinyl alco-
hol), poly(phenylene oxide), poly(ethylene imines), poly 
(acrylic acid), poly(vinyl amine) and combinations thereof. 
44 
14. The method of claim 1, wherein the therapeutic 
composition further comprises an active agent associated 
with the carbon nanomaterial. 
15. The method of claim 14, wherein the active agent is 
5 selected from the group consisting of anti-oxidants, anti-
inflammatory drugs, anti-cancer drugs, anti-diabetic drugs, 
siRNA, and combinations thereof. 
16. The method of claim 14, wherein the active agent is 
non-covalently associated with the hydrophilic carbon clus-
lO ter. 
17. The method of claim 1, wherein the therapeutic 
composition further comprises a targeting agent, wherein the 
targeting agent has recognition activity for a marker related 
15 to oxidative stress. 
18. The method of claim 17, wherein the marker is a cell 
surface protein that is up-regulated in response to oxidative 
stress. 
19. The method of claim 18, wherein the cell surface 
20 protein is selected from the group consisting of p-selectin 
mol_ec~les, transferrin receptors, angiotensin receptors, can-
n_abm01d receptors, epidermal growth factor receptors, adhe-
s10n molecules, chamiel proteins, and combinations thereof. 
. 20. The method of claim 17, wherein the targeting agent 
25 1s selected from the group consisting of antibodies, proteins, 
RNA, DNA, aptamers, small molecules, dendrimers, and 
combinations thereof. 
. 21. The method of claim 17, wherein the targeting agent 
1s non-covalently associated with the carbon nanomaterial. 
30 . 22. The method of claim 17, wherein the targeting agent 
1s covalently associated with the carbon nanomaterial. 
23. The method of claim 1, wherein a transporter moiety 
selected from the group consisting of camiabinoid mol-
ecules, cannabinoid molecule derivatives, HU-210 and com-
35 binations thereof is covalently linked to the PEG-HCCs. 
~4. 1:he method of claim 23, wherein the transporter 
m01ety 1s an unnatural enantiomer of a camiabinoid mol-
ecule. 
~5. 1:he method of claim 24, wherein the transporter 
40 m01ety 1s HU-211. 
26. _A method of treating oxidative stress in a subject, 
wherem_ t_he method comprises: administering a therapeutic 
compos1t10n to reduce the levels of reactive oxygen species 
in the subject, wherein the therapeutic composition includes 
45 a polyethylene glycol functionalized hydrophilic carbon 
cluster (PEG-HCC), and wherein an adamantane derivative 
is covalently bound to the terminus of the polyethylene 
glycol functionality of the PEG-HCCs. 
27. The method of claim 1 wherein the adamantane 
50 derivative is amantadine, memantine, rimantadine, dopa-
mantin, tromantadine, vildagliptin, or karmantadin. 
28. The method of claim 26 wherein the adamantane 
derivative is amantadine, memantine, rimantadine, dopa-
mantin, tromantadine, vildagliptin, or karmantadin. 
* * * * * 
